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DNA sensors of the innate immune system recognize nucleic acids such as double-
stranded DNA (dsDNA) and RNA:DNA hybrids of viral and bacterial origin. These 
are able to trigger an effective immune response via the production of interferons and 
cytokines. However, little is known about the existence of cytosolic nucleic acids in 
virus-free cells such as cancer or transformed cells, and its role in 
immunosurveillance and tumorigenesis. 
In this thesis, we show that cytosolic nucleic acids are present in various non-
infected human cell lines. DDX17 is found to bind both dsDNA and RNA:DNA 
hybrids, exhibiting different activity in accumulation of either nucleic acid. While 
DDR pathways were shown to regulate dsDNA accumulation, inhibition of RNA 
polymerase III, but not DNA polymerase abrogated cytosolic RNA:DNA hybrids. 
Further, as cytosolic RNA:DNA hybrids bind to several components of the 
microRNA machinery-related proteins, we identified microRNAs that were 
specifically regulated by RNA polymerase III, providing a potential link between 
RNA:DNA hybrids and the microRNA machinery.  
To investigate the role of cytosolic DNA in tumorigenesis, I crossed Eµ-Myc 
mice with Tnfa/Tbk1-double knockout mice, as Tbk1-deficient mice are 
embryonically lethal. To control for the effects of TNF-α, I also crossed Tnfa-
deficient mice. Mice were observed to have lower survival, due to the dominant role 
of TNF-α in proinflammatory and cell killing responses. Our data suggest that an 
efficient immune response is triggered in Eµ-Myc mouse model due to intracellular 
sensing of tumor cells, and possibly cytosolic DNA.   
 In summary, we have shown the presence of cytosolic dsDNA and 
RNA:DNA hybrids in virus-free human cells, and revealed possible substrates for 
sensing in tumor cells to trigger an immune response during tumor progression, as 
 ix 
evidenced by Eµ-Myc mice data. Presence of RNA:DNA hybrids were also found to 
be regulated by RNA polymerase III, which also affects microRNA expression, 
suggesting a pathway by which hybrids are modulated.  
 x 
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Chapter 1: Introduction 
 2 
1. Introduction 
Recognition of foreign DNA in the cytoplasm or organelles of a cell triggers 
a DNA-sensing immune response, where the DNA of either viral or bacterial origin 
activates receptors that signal through pathways to produce interferons and cytokines, 
and evoke an effective immune response. This mechanism serves to prevent the host 
cell from infections; however inappropriate activation by host DNA could damage 
the host cells leading to autoimmunity. 
In recent years, cancer immunotherapy has become a viable option as 
therapeutic strategies harness the immune system to target cancer cells. Previous 
research within the lab has shown an upregulation of NKG2D ligands (NKG2DL) in 
response to DNA damage, and that these processes are constitutively active in cancer 
cells (Lam et al., 2014a). NKG2D ligands are recognized by receptors found on 
natural killer (NK) cells that hone in to tumor cells for efficient immunosurveillance. 
In addition to NKG2D, we have also discovered the presence of cytosolic DNA in 
DNA-damaged murine tumors (Lam et al., 2014a), which may act as a substrate for 
DNA-sensing in tumor regression. However, the presence of cytosolic nucleic acids 
in human cells has yet to be investigated in detail.  
While DNA damage is involved in tumorigenesis, less is known about the 
coupled production of aberrant nucleic acids (dsDNA and RNA:DNA hybrids) via 
compromised genomic integrity. Dysregulation of these components may contribute 
to the accumulation of DNA damage, eventually leading to tumors. This study thus 
examines the presence of the cytosolic nucleic acids in cancer cell lines and 




1.1 Cancer and DNA damage 
Cancer evolves as a form of rapidly mutating and proliferating mass within 
the human body. Worldwide, cancer results in millions of death per year and is one of 
the leading causes of deaths in developed countries (Cancer, 2014). DNA damage is 
thought to contribute to tumorigenesis, due to high frequency of mutations within the 
genome. High replication rates of cancer cells would allow these cells to accumulate 
further errors that affect genetic encoding of information. Hence, cell cycle disruption 
is one of the most common ways by which oncogenetic mutations drive cells towards 
dysregulated proliferation, as reviewed by Williams and Stoeber (Williams and 
Stoeber, 2012).  
DNA is exposed to damage every day; sunlight contains ultraviolet rays that 
can cause up to 1 x 105 DNA lesions in a cell per day (Hoeijmakers, 2009). Exposure 
to exogenous carcinogenic chemicals also introduces DNA damage and mutates the 
genome. Compromised DNA integrity leads to accumulated mutations, resulting in 
genetic and epigenetic changes that lead to cancer, which will be discussed below. 
Damaged tissue also releases associated molecules that trigger inflammation as an 
immune response in the body (Medzhitov, 2008). While an acute phase of immune 
response leads to rapid clearance of damaged cells, long-term inflammation may lead 
to cancer due to continuous release of toxic reactive oxygen species (ROS) (Jaiswal 
et al., 2000).  
Hallmarks of cancer include sustained proliferation, inhibition of growth 
suppressors, invasion and metastasis, replicative immortality, angiogenesis induction, 
and resistance of cell death, as reviewed by Hanahan and Weinberg (Hanahan and 
Weinberg, 2011). Upstream of these processes, genomic instability and activation of 
cellular components and processes that regulate cells towards tumorigenesis deserve 
extensive study. Understanding immune sensing against DNA damage would also 
provide strategies to enhance specific anti-tumor immune responses. 
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1.2 Genomic instability  
Cell proliferation requires error-free replication to ensure high fidelity of 
genomic information. Cell cycle checkpoints and repair mechanisms during 
replication facilitate this process. On the other hand, cancer cells are prone to 
genomic instability due to high frequency of mutations within the genome of a 
cellular lineage that remain un-repaired. This genomic instability may result from 
cells being constantly challenged by both exogenous (UV, X- gamma-rays, viruses, 
DNA intercalating agents such as ethidium bromide) and endogenous (replication 
errors, ROS produced from normal metabolic by-products such as oxidative 
deamination) agents that cause DNA damage. Considering that the body is exposed to 
over thousands of DNA lesions in a day (Lindahl and Barnes, 2000), this contributes 
to the oncogenetic process as various regions of the genome are deleted or 
translocated, resulting in fusion genes, oncogene activation, or tumor suppressor gene 
(TSG) dysregulation, ultimately leading to cell transformation and tumors.  
 
1.2.1 Sources of DNA damage and genomic instability 
Replication stress 
The activation of oncogenes increases the proliferation rate of cells and 
deregulates the timing of replication. The high proliferative rate contributes to the 
increased accumulation of mutations, as the cell cannot repair damage before the next 
cell cycle proceeds. This phenomenon, also called replicative stress, directly affects 
the polymerase activity within cells, as reviewed by Aguilera and Gomez-Gonzalez 
(Aguilera and Gomez-Gonzalez, 2008). This results in the replication fork collapsing 
due to extended stalling or checkpoint inactivation. Genetic studies in yeast have also 
shown an importance of DNA ligase I and DNA polymerases for the accumulation of 




Another contributing factor to DNA breaks occurs with the transcription of 
microsatellite repeats, which allow for reading slippage in retroelements such as long 
interspersed nuclear elements (LINEs) and short interspersed nuclear elements 
(SINEs). Particularly in DNA trinucleotide repeats that are termed as fragile sites, 
these ubiquitous sites of replication may adopt secondary structures that affect 
replication (Burrow et al., 2010; Franchitto and Pichierri, 2011). Uncommon 
structures such as hairpins or DNA triplexes result in disassembly of the replisome, a 
protein complex that assembles on the DNA to carry out DNA replication (Gacy et 
al., 1995; Bacolla et al., 2006; Chen et al., 2010). These unique structural DNA 
signatures (hairpins and DNA triplexes) result in genetic instability, which are able to 
affect immune response in prostate and colorectal cancer (Egawa et al., 1995; 
Banerjea et al., 2004). 
 
Retroelements (non-coding DNA) 
Retroelements and transposons integrate into the genome of cells, and during 
duplication of these elements, reintegration into target sites might cause insertions 
and DNA breaks, associated with increased genomic instability (Belgnaoui et al., 
2006; Hedges and Deininger, 2007). Further, replication of retroelements like LINEs 
are prone to slippage via reverse transcription, and RNA:DNA hybrids accumulate if 
RNase H2 is not effective in degradation (Volkman and Stetson, 2014), which might 
contribute to DNA damage if RNA:DNA hybrids are not effectively removed. LINE-
1 was also shown to induce DNA damage in cancer cells (Belgnaoui et al., 2006)   
 
 
1.2.2 Double-stranded and single-stranded DNA 
The most common DNA breaks may result in free dsDNA or ssDNA 
depending on the type of damage caused in the genome. Single-stranded DNA breaks 
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(SSB) occur frequently as DNA lesions, due to oxidative stress by ROS that 
accumulate in normal cell metabolism (Caldecott, 2008). Replication forks that 
encounter unrepaired DNA lesions may result in replication blockage or collapse, 
leading to the formation of dsDNA breaks (DSB) (Kuzminov, 2001). Bacterial or 
viral DNA is also present in the cytoplasm in infected cells (Fredlund and Enninga, 
2014). Tumorigenesis is associated with prolonged DNA damage, which in turn is 
most commonly associated with DNA breaks, and in particular with DSB. Self-
dsDNA is capable of activating innate immune signaling, which is discussed further 
below in section 1.5.1 ‘Nucleic acid as a DAMP’. As such, the study of endogenous 
dsDNA is important in the context of cancer.  
 
1.2.3 RNA:DNA hybrids  
The presence of nuclear RNA:DNA hybrids is associated with the occurrence 
of DNA breaks and transcription (Komissarova et al., 2002; Hamperl and Cimprich, 
2014). RNA:DNA hybrids are shown to be involved with genomic instability via 
Rad51p and homologous recombination (Wahba et al., 2011; Biffi et al., 2013; 
Wahba et al., 2013). RNA:DNA hybrid formation in yeast by non-coding RNA has 
been shown to be able to bind to chromatin in a RNAi-machinery dependent manner 
(Nakama et al., 2012). Interestingly, the bacterial ortholog of Rad51p is RecA, an 
exchange protein that also promotes RNA:DNA hybrid formation via DNA repair 
(Kasahara et al., 2000). RecA is also known to bind dsDNA and facilitate ssDNA 
cross-exchange, likely important for recombination (Zaitsev and Kowalczykowski, 
2000). Thus RNA:DNA hybrid formation is associated with replication forks, and 
disruption of the complex might lead to release of hybrids along with genomic 
instability.  
While many studies mentioned above have focused on nuclear generation of 
RNA:DNA hybrids, the presence of cytosolic RNA:DNA hybrids is limited to 
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replication intermediates in virally-infected cells. It is unknown whether endogenous 
RNA:DNA hybrids are stably present in the cytosol of cells. Hence, the presence of 
RNA:DNA hybrids and its association with genomic instability poses questions for 
subsequent cellular activity and how it might relate to diseases that are associated 
with genomic instability, such as cancer. Here we list circumstances under which 
RNA:DNA hybrids can occur.   
 
Replication intermediates 
DNA replication occurs during the S phase of a cell cycle at replication forks, 
where DNA is separated into two strands called the leading and lagging strand, which 
act as templates for replication. Short RNA primers (9 or 10 nucleotides in length) are 
synthesized by primase and bind the DNA to initiate DNA polymerase downstream 
elongation of nascent DNA (Harrington and Perrino, 1995). These short RNA:DNA 
hybrids thus occur at replication sites, with accumulation of multiple RNA:DNA 
hybrids particularly at the lagging strand, due to the directionality of DNA that 
requires discontinuous replication. Replication fragments on the lagging strand are 
termed Okazaki fragments, and when the DNA polymerase collides with another 
downstream Okazaki fragment, 5’ end of the primer is eventually replaced with 
corresponding deoxyribonucleotides, as reviewed by (Burgers, 2009). 
DNA repair mechanisms were also found to associate with RNA:DNA hybrid 
formation. One example is Rad51p, which repairs DNA breaks in homologous 
recombination, and was found to regulate accumulation of RNA:DNA hybrids in 
yeast cells (Wahba et al., 2013).  
 
Transcription and R-loops 
Short 8 base-pair RNA:DNA hybrids form in RNA POL II mediated 
transcription (Komissarova and Kashlev, 1998; Kireeva et al., 2000). RNA:DNA 
hybrids also form within the RNA POL III complex, where shortening of the hybrid 
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via destabilization is a cue for transcription termination (Iben et al., 2011). Longer 
RNA:DNA hybrids, called R-loops can also form during stalled transcription. An R-
loop consists of a ssRNA transcript hybridizing to duplex DNA in transcription 
bubbles of RNA polymerases, and it can occur during stalling of transcription or 
during replication of mitochondria DNA (Aguilera and Garcia-Muse, 2012). R-loops 
are formed with the transcribed strand looping to form a RNA:DNA hybrid, though 
the non-transcribed strand is generally more sensitive to mutations (Beletskii and 
Bhagwat, 1996). Strikingly, R-loops are also associated with genomic instability 
during transcription for mRNA biogenesis, as reviewed by Hamperl and Cimprich 
(Hamperl and Cimprich, 2014), suggesting that the presence of RNA:DNA hybrids 
may occur in tandem with SSB or DSB. 
R-loops formation containing RNA:DNA hybrids are associated with ssDNA 
regions, and occur at regions of CpG islands, indicative of its GC skew and gene 
promoter regions (Ginno et al., 2012). Interestingly, this occurrence correlated with 
unmethylated status of promoters, thus regulating epigenetics within the genome for 
DNA replication to proceed. In fission yeast, RNA:DNA hybrids were shown to be 
associated with RNA-induced transcriptional silencing (RITS) complex, and affected 
heterochromatin formation (Nakama et al., 2012). RNA:DNA hybrids also drive 
transcriptional silencing by regulating RITS complex formation, which associates 
with siRNA generation. This intricate interplay of R-loop formation could provide a 
rapid mechanism by which RNA:DNA hybrid formation would regulate transposon 
silencing when required.  
R-loops are also related to generation of DSB in Escherichia coli (E. coli) 
cells and dependent upon ssDNA nicks and starvation (Wimberly et al., 2013). This 
stress-induced creation of R-loops and by extension, RNA:DNA hybrids, provides 
another means of aberrant nucleic acid accumulation in the nucleus, which would 




RNA:DNA hybrids also occur in G-quadruplexes and are detected in the 
nuclei of mammalian cells (Biffi et al., 2013; Lam et al., 2013; Xu and Komiyama, 
2013). G-quadruplexes are guanine-rich nucleic acid sequences that form a stable 
four-stranded looping secondary structure through Hoogsteen hydrogen bonding 
(Burge et al., 2006). Lam et al. 2013, isolated nuclear genomic DNA fragments 
containing G-quadruplex structures, demonstrating the presence of these structures 
stably in human genomic DNA (Lam et al., 2013), that can suppress transcription by 
stopping RNA POL II reads (Eddy and Maizels, 2008).  
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1.3 DNA damage response  
To protect genome integrity, cells first activate the DNA damage response 
(DDR), which counteracts the adverse consequences of DNA lesions by inducing 
repair of damaged DNA (Ciccia and Elledge, 2010). Damage that cannot be repaired 
results in cells undergoing apoptotic cell death or permanent cell cycle arrest.  
The DDR pathway triggers two types of sensing and repair mechanisms 
according to the type of damage that occurs (Fig. 1.1). ssDNA breaks occur with 
nucleotide misreading or point mutations, and are sensed by replication protein A 
(RPA) and the RAD9-RAD1-HUS1 (9-1-1) complex, via ATR phosphorylation to 
downstream CHK1 kinase. Conversely, DSB are sensed by the MRE11-RAD50-
NBS1 (MRN) complex, which phosphorylates ATM to activate CHK2 kinase. Signal 
amplification via ATM/ATR phosphorylation along with the Chk protein kinases 
allows for many downstream molecules to be activated, notably tumor suppressors 
such as Breast Cancer 1, Early Onset (BRCA1) and the p53 gene (Ho et al., 2006). 
Both pathways eventually lead to checkpoint arrest where the genome is assessed for 
DNA repair. Cyclin-dependent kinase (CDK) activity is also regulated to allow 
processing of DNA repair before cell cycle continues. Unrepaired damage may cause 
apoptosis or cellular senescence (Van Nguyen et al., 2007). Hence, the outcome of 
DNA repair determines if a cell re-enters the cell cycle, or is stalled in senescence if 
repair cannot proceed.    
The DDR also triggers an immune response with the upregulation of IRF1 
and IRF3 (Kim et al., 1999; Pamment et al., 2002), as NKG2D ligands activate NK 
cells in an ATM/ATR dependent manner (Gasser et al., 2005). Release of 
inflammatory cytokines interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α) 
attract immune cells to the microenvironment, so as to recognize and engulf damaged 
cells (Leek et al., 1998; Rodier et al., 2009). TNF signaling also activates NF-κB, a 
master regulator of cell survival (Biton and Ashkenazi, 2011). 
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Figure 1.1 The DNA damage response. The DNA damage response (DDR) follows 
a cascade of signaling steps that are triggered by genotoxic stress. dsDNA or ssDNA 
breaks in the genome are recognized by the MRE11-RAD50-NBS1 (MRN) complex 
or Replication protein A (RPA) and RAD9-RAD1-HUS1 (9-1-1) respectively. 
Downstream kinases ATM or ATR phosphorylate mediators along with important 
kinases Chk1 and Chk2 that regulate effectors, which in turn affect cell cycle 
progression, apoptosis, or cellular senescence. Modified with permission from Nature 
Reviews Cancer publication (Sulli et al., 2012), copyright 2012.  
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1.4 DNA repair 
The DDR activates two distinct pathways to regulate DNA repair (Sulli et al., 
2012). Figure 1.2 shows the types of DNA damage that trigger specific pathways of 
DNA repair. These require key repair proteins, which when mutated would result in 
formation of tumors. ssDNA repair occurs with mismatch repair (MMR), base 
excision repair (BER), or nucleotide excision repair (NER). NER recognizes base 
lesions and repairs it such that the damaged DNA is removed with the excision of a 
22-30 base ssDNA (Huang et al., 1992). Conversely, DSB repair is dependent on the 
stage of cell cycle replication. During most phases of the cell cycle, the cell utilizes 
non-homologous end-joining (NHEJ), which mediates repair by a sequence-
independent complex that comprises of DNA-PK and Ku70, and Ku80 proteins 
(Spagnolo et al., 2006). This, along with a less characterized microhomology-
mediated end-joining (MMEJ), is largely error prone. In contrast, the important S and 
G2 phases of a cell cycle utilize homologous recombination (HR) that ensures 
accurate repair via pairing of sister-chromatid templates. HR is usually associated 
with the MRN complex at the very early stage of cell cycle repair. Rad51 protein 
accumulates in the nucleus after DNA damage and forms foci, along with BRCA2 to 
repair DSBs (Tarsounas et al., 2004). 
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Figure 1.2 DNA repair mechanisms in DNA damage help to preserve genomic 
stability. The genome is assaulted with different types of DNA damage, and DNA 
repair mechanisms exist for different types of lesions, where the DDR recruits 
specific proteins that help to process the genome for repair. Tumor types found to be 
associated with a defect in each repair pathway are shown. BER, base excision repair; 
NER, nucleotide excision repair; NHEJ, non-homologous end-joining. Modified with 





1.5 DAMPs and PAMPs  
Characteristics of DAMPs and PAMPs 
In addition to the DDR, irradiation or genotoxic compounds also trigger the 
release of danger-associated molecular patterns (DAMPs) or alarmins, as reviewed by 
Oppenheim and Yang, and Bianchi (Oppenheim and Yang, 2005; Bianchi, 2007). 
This is in contrast to pathogen-associated molecular patterns (PAMPs) that are non-
self antigens released in response to pathogen infection by viruses or bacteria, as 
reviewed by Mogensen (Mogensen, 2009). DAMPs and PAMPs can be categorized 
into lipid-related, sugar-related, metabolite-related, nucleic acid-related, and protein 
related, as reviewed by Jounai and colleagues, and Srikrishna and Freeze (Srikrishna 
and Freeze, 2009; Jounai et al., 2012). Endogenous DAMP signals may be released 
from necrotic cells, apoptotic cells, or secreted from activated immune cells during 
microbial, viral infection, or cellular injury (Srikrishna and Freeze, 2009; Jounai et 
al., 2012) . Examples of DAMPs include DNA, RNA, ROS (reactive oxygen species) 
and nucleotides, as well as proteins such as high mobility group box 1 (HMGB1) and 
S100 (Wang et al., 1999; Boyd et al., 2008; Jounai et al., 2012). These elicit an 
inflammatory response leading to cell clearance and tissue repair. DAMPs have been 
shown to play an important role in various infectious and autoimmune diseases 
(Cunha et al., 2012; Tsai et al., 2014).  
 
Pathways for sensing DAMPs and PAMPs 
DAMPs and PAMPs are detected by pattern recognition receptors (PRRs) as 
part of the host sensing system. As reviewed by Takeuchi and Akira, PRRs may be 
membrane-bound, or cytosolic in nature (Takeuchi and Akira, 2010). Examples of 
PRRs include Toll-like receptors (TLRs), nucleotide oligomerization domain (NOD)-
like receptors (NLRs), retinoic acid-inducible gene-I (RIG-I)-like receptors (RLRs), 
and other cytosolic nucleic acid sensor receptors. Of note, TLR receptors 3, 7, and 9, 
which mainly sense nucleic acids are primarily localized in the endosome. Activation 
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of PRRs trigger specialized signaling pathways that result in secretion of type 1 
interferon (IFN), or proinflammatory cytokines such as IL-1β and IL-18. These may 
amplify inflammatory responses via maturation of antigen-presenting cells (APCs) 
(Li et al., 2004), and activate specific T cell immune responses such as cell 
cytotoxicity, leading to cell death. Figure 1.3 shows the types of DAMPs and 
PAMPs, with corresponding intracellular nucleic acid sensing systems that activate 
the immune system, leading to host defense against pathogen infection and 
autoimmunity.  
 
Self vs. non-self nucleic acid antigens 
A fundamental question regarding nucleic acids that are part of DAMPs and 
PAMPs is how their PRRs ignore self nucleic acids. In particular, nucleic acid 
structures comprise of a relatively uncomplicated composition based on four 
nucleotides, making it difficult to chemically distinguish self and non-self nucleic 
acids. Thus this may cause erroneous recognition of self-antigens, leading to 
unwanted inflammation against antigens.  
Structural modifications of nucleic acids may be a solution to this 
conundrum; these are present in viral replication but absent in self-nucleic acids. As 
an example, 5’ triphosphate (5’ppp)-dsRNA is a modified structure found only in 
replicating RNA viruses, and is sensed by RIG-I to activate IFN-α (Hornung et al., 
2006; Schlee et al., 2009). However this is not always foolproof, as the B-form 
structure of canonical DNA (Watson and Crick, 1953) also induces TLR-independent 
activation of interferon-beta and NF-κB (Ishii et al., 2006). This suggests that self-
activation of PRRs may occur, resulting in autoimmune diseases. In addition, other 
DNA structures such as Z-DNA and G-quadruplexes also associate with genomic 
instabilities, reviewed by Zhao and colleagues (Zhao et al., 2010), which might lead 
to DSB, thus triggering the DDR and the innate immune response (Rodriguez et al., 
2012).  
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Compartmentalization of PRRs also places importance on whether an antigen 
is sensed by cells. DAMPs are sensed by various sensors located in organelle 
compartments or in the cytosol, to ensure immediate detection of foreign antigens. 
Toll like receptors (TLRs) are located on the membranes of such compartments, 
while others such as NLRP3 and DAI are located in the cytosol. Thus, accumulation 
of DAMPs in unwarranted organelle compartments might trigger an unwanted 








Figure 1.3 Pathway for sensing of nucleic acids. The host sensing system 
encompasses various TLRs and cytosolic sensors that detect endogenous autoantigens 
such as RNA, DNA, or immune complexes, or exogenous antigens from pathogens 
such as viruses and bacteria. Activation of the host sensors that may locate at 
endosomes or the cytosol leads to a cascade signaling which results in production of 
inflammatory cytokines and type 1 IFNs as a host defense system for elimination of 
pathogens or diseased cells. Immune dysregulation thus disrupts the host defense 
system leading to pathogen invasion or autoimmunity. Reprinted with permission 




1.5.1 Nucleic acid as a DAMP  
Accumulation of cytosolic nucleic acids due to genomic instability 
mechanisms mentioned in the previous section could provide another means by 
which aberrant DNA is detected in the cytoplasm by DNA sensors, acting specifically 
as a DAMP in tumor cells. This would provide a means for the immune system to 
detect cancerous cells via induction of proinflammatory cytokines, chemokines and 
ligands for activating immune receptors (Gasser and Raulet, 2006a; Gasser and 
Raulet, 2006b; Weitzman et al., 2004).  
 
dsDNA and ssDNA 
A variety of DNA sensors have been discovered in the cytosol, which leads 
to signaling by STING or MYD88 for interferon and cytokine response. Some 
evidence has shown that leukemic tumor cells release DNA that is able to disrupt 
bone marrow and causes apoptosis of surrounding non-tumorigenic cells (Dvorakova 
et al., 2013). Conversely, cells were found to be non-responsive to ssDNA 
transfection, since dsDNA but not ssDNA could trigger IFN and IL-8 production in 
HEK293, suggesting that dsDNA is a more potent immunogen (Ishii et al., 2006).  
Evidence of nucleic acid DAMPs in the development of autoimmune disease 
has been shown in Dnase1-deficient mice that develop high titers of anti-nuclear 
antibodies (ANA) with reactivity to nucleosomes, ssDNA, and dsDNA, suggesting 
reactivity of ANA to DNA-protein complexes (Napirei et al., 2000). These mice also 
show characteristics of systemic lupus erythematosus (SLE). Further, SLE patients 
have been found to have mutations in DNASE1 (Yasutomo et al., 2001). Interestingly, 
UV-damaged DNA transfected into mouse dendritic cells (DCs) requires STING but 
not TLR9 (Gehrke, Immunity, 2013). The pathway by which cell damage activates 
downstream signaling remains much to be studied.  
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TREX1 is a DNA-specific exonuclease in mammalian cells (Lindahl et al., 
2009). Yang et al. showed that TREX1 relocates to the replication foci in the nucleus 
after DNA damage (Yang et al., 2007), suggesting its role in DNA repair.  
Trex1-deficient mice accumulate ssDNA originating from endogenous 
retroelement replication, with higher expression of Tnfα, IL1b, Nos2 and cxcl10 in 
brain tissues (Stetson et al., 2008). High levels of TREX1 are expressed in immune 
cells, induced by proinflammatory stimuli. Upon UV stimulation, TREX1 
translocates from the cytoplasm to the nucleus of cells (Christmann et al., 2010). 
 
RNA:DNA hybrids 
RNA:DNA hybrids were first proposed to play a role in immune sensing, 
when RnaseH2 mutation leads to Aicardi-Goutieres syndrome (AGS), a 
neuroinflammatory disorder suggesting the processing of RNA:DNA hybrids are 
important to prevent inflammatory response (Crow et al., 2006). Additionally, 
RnaseH deficiency in E. coli resulted in higher killing ability of macrophages (Crow 
et al., 2006), suggesting that increased amounts of RNA:DNA hybrids enchance 
activation of the innate immune system.  
Eukaryotic cells have two types of RNase H (1 and 2) that degrade 
RNA:DNA hybrids. RNase H1 hydrolyzes RNA through its hybrid binding domain, 
which preferentially binds to RNA:DNA hybrids by 25-fold over dsRNA (Nowotny 
et al., 2008). RNase H2 is a trimeric complex that hydrolyzes 5’-phosphodiester 
bonds of the RNA strand of a RNA:DNA hybrid (Rychlik et al., 2010). Replicating 
retroviruses require RNase H activity, which degrades the ssRNA strand from the 
nascent dsDNA viral genome during reverse transcription (Wohrl and Moelling, 
1990). Both types of Rnase deletions are embryonically lethal; RnaseH1 deletion 
results in mitochondrial DNA depletion (Cerritelli et al., 2003) while RnaseH2 
deletion results in chromosome instability and elevated DNA damage (Reijns et al., 
2012). Notably, RNase H enzymes may also help to suppress R-loop formation. Of 
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note, the human genome contains large numbers of stable human endogenous 
retroviral (HERV) insertions, and suppression by RNase H would prevent replication 
of these transcripts (de Parseval et al., 2003). 
Cytosolic RNA:DNA hybrids arising from various sources can be sensed by 
intracellular cytosolic sensors (Fig. 1.4). Furthermore, immunostimulatory properties 
have been shown by RNA:DNA hybrids through sensing by TLR9 in murine DCs 
(Rigby et al., 2014). Following transfection of viral 60 bp RNA:DNA hybrids, IL-6, 
IFN-α, and TNF-α cytokines were produced by both murine DCs and human 
peripheral blood mononuclear cells (PBMCs). These responses were found to be 
MyD88-dependent. Bacterial RNA:DNA hybrids were also found to trigger the 
NLRP3 inflammasome, with cytosolic hybrids being detected in infected 
macrophages within an hour of infection (Kailasan Vanaja et al., 2014).  
 
RNA:DNA hybrids from infection by bacteria or viruses 
RNA:DNA hybrid formation has been widely known to occur during reverse 
transcription in retroviral infection (Takano and Hatanaka, 1975a; Horton and Finzel, 
1996). RNase H activity degrades the RNA strand of the formed RNA:DNA hybrid 
after reverse transcription, releasing the nascent DNA to hybridize to the genome. 
Strikingly, RNA:DNA hybrids are found in endosomal compartments within cells 
(Rigby et al., 2014), suggesting an engulfment process related to the sensing of these 
hybrids from viral or bacterial sources. RNA:DNA hybrids are transiently generated 
in the cytosol of virus-infected cells via reverse-transcription of an viral RNA 
template strand (Takano and Hatanaka, 1975a, b; Horton and Finzel, 1996; Abbink 
and Berkhout, 2008). During re-integration of retroelements, reverse transcription 
occurs with the formation of RNA:DNA hybrids, which is thought to be inhibited by 
TREX1 or RNase H2 (Stetson, 2012). Increased RNA:DNA hybrids facilitate 
cytosolic dsDNA accumulation through reverse transcription, which may trigger 
DNA sensors such as IFI16 and cGAS for sensing via STING.  
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Figure 1.4 Nucleic acids are sensed by intracellular cytosolic sensors. While 
ssRNA in the cytosol are sensed by TLR7 in the endosome, or RIG-1 in the cytosol, 
ssRNA from endogenous retrovirus or retrovirus in the cytosol can form RNA:DNA 
hybrids. RNA:DNA hybrids are normally degraded by RNase H. However, when 
RNA:DNA hybrids accumulate in the endosome, they are recognized by 
TLR9/MyD88 signaling pathway. RNA:DNA hybrids can also be reverse transcribed 
into dsDNA which can be sensed by DNA sensors IFI16, and cGAS. Reprinted with 
permission from EMBO (Jensen and Paludan, 2014) copyright 2014.  
 
 
1.6 The RNA Polymerase (POL) III family 
RNA polymerases are known to transcribe a nascent ssRNA from double 
stranded DNA. Most notably, RNA POL II is required for the transcription of 
mRNAs in genome duplication and cell division (Yonaha et al., 1995). The unique 
interaction of RNA within unwound dsDNA provides the formation of a temporary 
RNA:DNA hybrid. However in recent years, RNA POL III has rose in prominence as 
a cytosolic DNA sensor that recognizes synthetic A-T rich DNA (Ablasser et al., 
2009; Chiu et al., 2009). It then reverse transcribes DNA via the formation of 
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RNA:DNA hybrids, to produce dsRNA that triggers RIG-I to induce an interferon 
response. In particular, dysregulation of RNA POL III is also associated with cancers 
(Winter et al., 2000; Moinzadeh et al., 2014). Given the role of RNA POL III in the 
formation of nucleic acids such as RNA:DNA hybrids that were previously shown to 
be immunogenic (Fig. 1.4), we chose to focus on RNA POL III and its functional role 
in immune sensing and cancer.  
  
1.6.1 RNA POL III activity 
RNA POL III is the largest RNA polymerase that contains 17 subunits, 
including a DNA binding site, functioning to catalyze the transcription of nuclear 
DNA into RNA (Dieci et al., 2007; Lorenzen et al., 2007; Dieci et al., 2013). In 
contrast to POL I, which is essential for the transcription of ribosomal RNA, and POL 
II, which is required for a wide variety of transcripts including protein-coding 
mRNAs and microRNAs (miRNA), POL III-RNA transcripts are characterized by 
their non-coding infrastructural functionality (Sentenac, 1985). Forms of this enzyme 
were purported to localize within different cellular regions; IIIB is detected in the 
cytosol, while IIIA is found mainly in the nucleus. While it is found both in the 
nucleus and cytoplasm, two-thirds of RNA POL III activity was in the cytoplasm 
(Jaehning and Roeder, 1977).  
POL III-driven RNA transcripts have roles in multiple cellular processes 
(Fig. 1.5). The most fundamental role of POL III transcription involves providing a 
supply of tRNAs required for the translation of mRNA read by ribosome to produce a 
nascent polypeptide (Weinmann and Roeder, 1974). POL III also transcribes for 5S 
rRNA, which is required in the assembly of a functional ribosome. While majority of 
the above-mentioned RNA POL III transcripts are involved in protein synthesis, a 
portion of RNA POL III transcripts that are non-coding (nc) have been studied for 
their role in regulating genetic activity to affect cellular processes (Dieci et al., 2013).  
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RNA POL III-driven ncRNAs include U6 small nuclear RNAs (snRNAs) that 
assemble in splicesosome (Kambach et al., 1999) to assist in cleavage of introns in 
genomic sequences to form a functional mRNA for translation, and short interspersed 
nuclear element (SINE)-encoded RNAs which are widely found in the human 
genome (Kramerov and Vassetzky, 2005; Dieci et al., 2013). Interestingly SINEs are 
upregulated in response to DNA damaging agents (Hagan and Rudin, 2007), 
signifying its role in DNA breakage and DDR. In particular, Alu RNAs, a subset of 
SINEs can downregulate protein expression as anti-sense inhibitors of mRNAs 
maturation or translation (Pagano et al., 2007).  
Human RNA POL III is also able to transcribe microRNAs (miRNAs), as 
regions of POL III-occupied miRNAs were identified (Ozsolak et al., 2008). 
MiRNA-coding sequences were also found within POL III transcribed Alu repeats of 
the human genome, suggesting the connection between repetitive elements, POL III, 







Figure 1.5 RNA POL III transcripts and roles in cellular processes. Various types 
of non-coding RNAs transcribed by RNA POL III act in the nucleus (Blue boxes) and 
cytoplasm (Green boxes) to regulate cellular processes. Alu transcripts have poorly 
defined functions and are indicated with a question mark. Modified with permission 
from ScienceDirect: Trends in Genetics (Dieci et al., 2007) copyright 2007.  
 
1.6.2 RNA POL III in immune sensing 
Cells transformed by simian virus 40 (SV40) were shown to upregulate POL 
III transcription components (Valentine and Smith, 2010). More recently, RNA POL 
III was also found to transcribe synthetic AT-rich DNA and Epstein-Barr virus 
(EBV)-encoded RNAs in the cytosol, a distinct feature from its original nuclear 
genome transcription (Ablasser et al., 2009; Chiu et al., 2009). RNA POL III 
transcribes the dsDNA into ssRNA containing 5'-triphosphate (5'-ppp), which is 
recognized via RIG-1 and signaled through the TBK1/IRF3 pathway to produce IFN-
β. RNA POL III inhibition also blocked IFN-β production in response to infection 
with bacterium Legionella pneumophila, viruses herpes simplex virus type 1 (HSV-
1), and Epstein Barr virus (EBV) (Ablasser et al., 2009; Chiu et al., 2009). Vaccinia 
virus E3 protein was further shown to inhibit this RNA POL-III dsDNA-sensing 
pathway (Valentine and Smith, 2010), suggesting the significance of this pathway in 
the recognition of viruses for killing of infected cells. 
  
1.6.3 RNA POL III in cancer 
RNA POL III transcribes tRNAs required for protein synthesis and ncRNAs 
that can modulate gene expression for cell processes (Kunkel et al., 1986; Canella et 
al., 2010). POL III was also implicated in DNA sensing and the induction of IFN-β 
(Ablasser et al., 2009; Chiu et al., 2009). Given its role in modulating oncogenes and 
tumor suppressor genes, and immune sensing, POL III activity was consequently 
found to be associated with cancer progression. POL III transcripts were initially 
found to be elevated in transformed cells (Singh et al., 1985; Carey et al., 1986); POL 
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III-driven transcripts BC1 and BC200 were only detectable in tumor cells while 
normal neighboring tissues did not express these transcripts (Chen et al., 1997a; Chen 
et al., 1997b). Mice with melanomas had hyperactive POL I and III, while POL II 
levels remained normal (Schwartz et al., 1974). Overexpression of RNA POL III was 
found in human ovarian carcinoma (Winter et al., 2000). RNA POL III was found to 
interact with many proteins involved in cell proliferation and known tumor regulating 
proteins, e.g. retinoblastoma (RB) (Gjidoda and Henry, 2013) and BRCA1 (Veras et 
al., 2009). Decreased RNA POL III transcription factor Brf1 expression increased 
anchorage-independent cell proliferation, a characteristic of cancer cells, alongside a 
decrease in RNA POL III transcription (Johnson et al., 2008). On the other hand, 
tumor suppressor PTEN, which is commonly mutated in cancers, represses RNA 
POL III transcription (Woiwode et al., 2008). RNA POL III transcripts and 
associated transcription factors are hence able to target tumor suppressor genes and 
oncogenes (Marshall and White, 2008) that normally lead to cancers.  
 
1.6.4 Clinical trials using RNA POL III inhibitors 
RNA POLs are potential targets in drug design for cancer therapy, due to 
their nature in transcribing genes essential for cell function, such that dysregulation of 
these processes result in cancer. For example, clinical trials for cancer therapy are 
underway by using RNA POL II inhibition to result in cell cycle arrest (Byers et al., 
2005). Additionally, RNA POL III may be another potential cancer therapy candidate 
given its role in cell proliferation and contribution to oncogenesis. For example, RNA 
POL III antibodies were found to be risk factors for scleroderma renal crisis in 
systemic sclerosis patients (Hesselstrand et al., 2012). 
Drugs have also been manufactured to combat the transcription pathways 
targeted RNA polymerases. TAS-106 is a RNA polymerase inhibitor of I, II, and III, 
and was used in a clinical trial of platinum-failure metastatic head and neck cancer or 
solid malignancies. This was terminated due to insufficient treatment benefits and 
 27 
complications at high dosage levels, although complementary treatment with other 
drugs was considered for further study (Hammond-Thelin et al., 2012; Tsao et al., 
2013). However, Favipiravir (T-705) is a RNA-dependent RNA polymerase inhibitor 
of influenza viruses. Its active form, favipiravir-ribofuranosyl-50-triphosphate (RTP) 
acts as a pseudo-purine nucleotide to prevent further incorporation of nucleotides for 
viral RNA replication (Furuta et al., 2013).  
 
1.7 MicroRNAs (miRNAs) 
1.7.1 Biogenesis 
MiRNAs are 18-25 nucleotide-long RNAs that post-transcriptionally regulate 
gene expression by complimentary binding to an mRNA strand to mediate processes 
such as apoptosis, proliferation, and cell signaling (Kloosterman and Plasterk, 2006; 
ChunJiao et al., 2014). MiRNAs are located within the genome, and initially 
transcribed as primary miRNAs (pri-miRNAs) by RNA POL II or III in the nucleus 
(Lee et al., 2004). This process may be dependent on gene transcription if the miRNA 
is located within the intron (intronic region) of a host gene, or independent pri-
miRNA transcription if the miRNA has its own promoter (intergenic region) 
(Ozsolak et al., 2008). Formation of a mature miRNA requires a two-step processing 
that is elaborated in Figure 1.6 that starts with cleavage of the primary miRNA to 
form a stem loop precursor miRNA (pre-miRNA) by the DROSHA-DGCR8 complex 
(Han et al., 2004). Many proteins also interact to regulate pri-miRNA processing, 
including BRCA1 oncogene (Kawai and Amano, 2012), and RNA helicases DEAD 
(Asp-Glu-Ala-Asp) box helicase 5 and 17 (DDX5/DDX17) (Fukuda et al., 2007). 
Subsequent export to the cytoplasm is mediated by exportin 5 (XPO5) with Ran-
GTP, and a second-step processing by Dicer-TRBP complex that cleaves the hairpin 
loop to release a miRNA duplex (Yi et al., 2003; Han et al., 2004). Further 
unwinding and loading of the mature single-stranded miRNA into the RNA-induced 
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silencing complex (RISC) allows it to function in RNAi gene silencing, targeting its 
complementary mRNA. Degradation of pre-miRNAs is regulated by MCPIP1 





















Figure 1.6 Biogenesis of microRNA and its regulation by interacting factors. 
MiRNAs are transcribed from the intronic or intergenic portions of the genome by 
RNA POLs II or III (POL II/III) into pri-miRNAs. The DROSHA-DGCR8 complex 
binds and further processes the miRNA by cleaving to release the stem loop, thus 
generating a pre-miRNA, which is exported via XPO5-containing nuclear export 
receptor-complex into the cytosol. The cytosolic Dicer-TRBP complex then binds 
and removes the hairpin loop to produce a miRNA duplex, of which one strand of the 
duplex will be a mature miRNA and loaded into the RISC complex to execute gene 
silencing against a transcript complementary to its sequence. MiRNA degradation is 
regulated by XRN2 and hPNPase that digest single-stranded miRNAs, and MCPIP1 
that removes unprocessed pre-miRNAs. Modified with permission from Landes 
Bioscience: Cell Cycle (Wang and Taniguchi, 2013), copyright 2013.  
 
1.7.2 MiRNAs in DNA damage  
MiRNA biogenesis is affected by DNA damage, which is to be expected 
since miRNAs regulate expression of many genes, including DNA damage and repair 
genes. Transcription of miRNA can be regulated in response to DNA damage. P53 is 
a tumor suppressor that pauses the cell cycle, activates DNA repair proteins, and 
directly targets miR-34a for upregulation, providing a positive feedback loop to 
increase tumorigenesis (Okada et al., 2014). MiR-192 and miR-215 are also 
dependent on p53 and are upregulated in response to genotoxic stress (Braun et al., 
2008; Georges et al., 2008). MiRNA export has been shown to be dependent on 
ATM/ATR, as neocarzinostatin-mediated DNA damage results in XPO5 mediated 
transport of miRNAs into the cytoplasm (Wan et al., 2013). MiR-138 decreases H2A 
Histone Family, Member X (H2AX) expression in human cells, and affects genomic 
stability and DNA repair (Wang et al., 2011). Other pathways that are affected by 
miRNAs include cell cycle checkpoint, DNA repair, and DDR-dependent pathways 
(Wang and Taniguchi, 2013). MiRNA is purported to involve both upstream and 
downstream of DNA damage signaling, as some miRNAs affects DNA damage 
molecules, while DNA damage also directly affect miRNA transcription. Thus, a 
potential feedback loop between miRNAs and DNA damage might regulate both 
signaling pathways in cellular processes.  
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1.7.3 MiRNAs in cancer 
Human microRNA genes were found to locate within putative cancer-
associated genomic regions and fragile sites along with breakpoints (Calin et al., 
2004). The possibility of these intronic miRNAs to be expressed when cancer-
associated genes are transcribed, hints at the role that miRNA might play in 
regulating genes that affect tumorigenesis. Oncogenic miRNAs (oncomirs) is a group 
of miRNAs that target mRNAs coding for tumor suppressor genes or oncogenes, thus 
regulating these genes and their downstream effects on cellular processes associated 
with cancer, such as apoptosis and proliferation (Macfarlane and Murphy, 2010). For 
instance the Let-7 family down regulates c-Myc mRNA and protein expression to 
reduce proliferation in Burkitt lymphoma cells (Sampson et al., 2007). A 
comprehensive list of miRNA involved in various human cancers is shown in 
Babashah and Soleimani (Babashah and Soleimani, 2011).   
Many RNA-binding proteins such as DDX5 and DDX17, that regulate 
miRNA biogenesis, are also implicated in cancer, signifying an interplay of the 
miRNA processing machinery and other cellular processes (van Kouwenhove et al., 
2011). Strikingly, pre-miRNAs tend to accumulate in tumor cells as compared to 
normal tissue (Thomson et al., 2006) with the repression of mature miRNA formation 
(Kumar et al., 2007), allowing for cellular transformation and progression towards 
tumorigenesis. For instance, XPO5 mutations cause a similar decrease of mature 
miRNA accumulation in human tumors, and XPO5 knockdown enhances tumor 
progression (Kumar et al., 2007). Impaired miRNA biogenesis also escalates 
tumorigenesis, as DGCR8, Drosha, and Dicer knockout tumor cells proliferate 
rapidly and increase tumor growth over time (Zhang et al., 2011b). 
As miRNA profile changes are observed in many types of cancers, the use of 
miRNA detection as a biomarker for cancer, or anti-miRNA therapy deserves to be 
investigated. In addition to cancer, autoimmune diseases such as systemic lupus 
erythematosus (SLE) have shown that miRNA profiles differ in patient subsets with 
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different autoantibody specificities (Chauhan et al., 2014). This is significant as SLE 
patients have heterogeneous clinical manifestations and identifying common subsets 
allows targeted treatment of these patients. In particular, Chauhan et al. found that 
patients expressing anti-dsDNA also had dysregulated miRNAs targeting cytokine 
signaling. This suggested that presence of anti-dsDNA could affect the immune 
system via the specific subset of dysregulated miRNAs. Cell-free circulating 
miRNAs also vary in profiles in response to disease states, while some studies 
suggest it as a blood cell-based phenomenon (Pritchard et al., 2012). Use of anti-
miRNA therapy such as locked nucleic acid (LNA)-modified oligonucleotides to 
knockdown levels of oncomirs could also decrease tumorigenesis (Orom et al., 2006). 
The highly regulatory nature of miRNAs on cellular processes makes it a prime target 
for investigation, as miRNA profile expression marks a specific state of cancer tissue. 
 
1.8 Eµ-Myc mouse model 
Contribution of DDR with miRNA regulation to affect tumor progression in a 
hematological cancer places the Eµ-Myc transgenic mouse as an ideal mouse model 
to study in the context of how endogenous nucleic acids affect both mechanisms, 
resulting in tumorigenesis.  
Mouse models have been used to study tumor development and in vivo 
immune responses (Anderson and Bluestone, 2005; Cheon and Orsulic, 2011; 
Croxford et al., 2013; Lam et al., 2014a). In particular, the Eµ-Myc mouse model is 
selected as the mouse overexpresses the Myc oncogene, in which Myc is associated 
with DNA damage (Adachi et al., 2001; Vafa et al., 2002). Myc expression induces 
ROS activity along with partial disruption of the DDR (Vafa et al., 2002). Myc-
induced replication stress via accelerated cell cycle passage also results in genomic 
instability, karyotypic abnormalities, and gene amplification (Felsher and Bishop, 
1999). Further, Atm-deficient Eµ-Myc mice display defective DDR and accelerated 
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lymphoma growth. This results in lower survival rates as compared to Eµ-Myc mice, 
suggesting a DDR-dependent tumorigenesis of these mice (Reimann et al., 2007). 
This finding was extended to solid malignancies as inactivated Atm also accelerated 
tumorigenesis in a K5 Myc mouse model exhibiting Myc-overexpressed squamous 
epithelium (Pusapati et al., 2006).  
In addition to the effects of DNA damage on Eµ-Myc mouse tumorigenesis, 
oncogenic non-coding miRNAs also modulate tumor formation. An example of 
oncogenic miRNAs is the Mir-17-92 cluster, of which its overexpression correlates 
with reduced apoptosis and aggressive tumors in Eµ-Myc mice (He et al., 2005). The 
c-Myc oncogene has been shown by chromatin immunoprecipitation to bind directly 
to the mir-17 cluster locus, providing strong indication of direct regulation of 
miRNAs by c-Myc (O'Donnell et al., 2005). 
Eµ-Myc mice develop B cell lymphomas by day 60 of age, and they display 
phenotypic similarity to human acute lymphoblastic leukemia (ALL) (Adams et al., 
1985; Harris et al., 1988). The c-Myc oncogene of Eµ-Myc mice is under the control 
of the immunoglobulin heavy chain enhancer (Eµ) and this dysregulation is 
genetically homologous to that of human Burkitt lymphoma (Adams et al., 1985). 
Since Myc dysregulation is found in 70% of human malignancies, as reviewed by 
Meyer and Penn (Meyer and Penn, 2008), the Eµ-Myc mouse model is therefore 
important in the study of tumorigenic malignancies.  
 One of the major characteristics of the Eµ-Myc transgene-hemizygous mice is 
the early accumulation of polyclonal tumorigenic B lymphocytes, following which 
there is sharp regression in the periphery but not bone marrow of mice between 6-8 
weeks of age (Harris et al., 1988; Sidman et al., 1993). Eventually B-cell lymphoma 
develops at the late stage by 15-20 weeks of age, where the prior regression is 
attributed to early anticancer immune signaling. A small subset of aged mice over 14 
weeks of age had lower pre-B cell levels in spleen and bone marrow as compared to 
younger Eµ-Myc mice (Langdon et al., 1986).  Our group has examined the 
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regression phase of tumor cells and shown increased NK and T-cell 
immunosurveillance, along with activation of the DNA damage response and 
DNAM-1 ligand expression, resulting in spontaneous rejection of these tumor cells in  
Eµ-Myc mice (Croxford et al., 2013).  
 
1.9 Aims 
While cytosolic nucleic acids have been largely characterized with respect to 
viral and bacterial infections, less is known about the presence of cytosolic nucleic 
acids in non-infected human cancer cells and their potential role in cancer 
progression. The following hypotheses drive the formation of three broad areas in my 
research project: 
a. dsDNA in the cytosol of human tumor cells is dependent on DDR, similar to 
that in mouse tumor cells. 
b. Cytosolic RNA:DNA hybrids exist in human tumor cells and are regulated by 
mechanisms that may be similar to cytosolic dsDNA. 
c. The tumor regression phase of the Eµ-Myc mouse model is activated by 
TBK1 signaling pathway of innate immune sensing. 
d. This sensing results in the production of proinflammatory cytokines such as 
TNFα to initiate an anti-tumor response.  
Thus, the three broad areas (illustrated in Fig. 1.7) that my research entails are:  
1.  Characterization of dsDNA in human tumor cells;  
2.  Discovery of RNA:DNA hybrids in human tumor cells and mechanisms of 
generation;  
3.  Phenotypic characterization of Tbk1-deficient Eµ-Myc mice and Tnfα-
deficient Eµ-Myc mice (Generation of these mice was carried out in Japan.) 
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Therefore, the aim of my PhD project is to characterize the presence of dsDNA 
and RNA:DNA in the cytosol of human cells, and to investigate the molecules 
involved in their interaction, thus revealing a possible role of these nucleic acid 
structures. As part of the research on the role of cytosolic DNA in tumor sensing and 
progression, it is appropriate to study the role of TBK1 and TNF-α using the Eµ-Myc 
tumor mouse model. This study contributes to the field of DNA-sensing and the 
immune response in tumorigenesis by extending the scope of nucleic acids that may 




Figure 1.7 Overview of the thesis areas of research. The three broad areas of 
research are numerically listed (blue) in the schematic diagram: 1) The study of 
cytosolic dsDNA in human tumor cells, 2) the discovery of RNA:DNA hybrids and 
its characterization, and 3) Phenotypic characterization of Tbk1-deficient Eµ-Myc 










Chapter 2: Materials and Methods 
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2.1 Mice and cells 
C57BL/6 mice were purchased from the Centre for Animal Resources at 
Osaka University. Eµ-Myc transgenic mice on a C57BL/6 background were 
purchased from Jackson Laboratory (USA). Tnf-/- mice on a C57BL/6 background 
and Tnf-/-Tbk1-/- mice on a 129/Ola3C57/BL6 background were provided by Prof. K. 
Ishii (National Institute of Biomedical Innovation, NIBIO) and Prof. S. Akira 
(iFREC, Osaka University), as described previously (Hemmi et al., 2004; Ishii et al., 
2006; Ishii et al., 2008). Mice were bred and housed according to the guidelines by 
the National Institute of Biomedical Innovation. The human colorectal 
adenocarcinoma (LOVO and HT29), colorectal carcinoma (HCT116), lung 
adenocarcinoma (A549), monocytic cell lines (THP-1) were purchased from ATCC 
(USA). Cells were grown in Dulbecco’s modified Eagle’s medium (Nacalai Tesque, 
Japan), supplemented with 10% fetal bovine serum (Cell Culture Bioscience, Japan), 
1% penicillin/streptomycin (Nacalai Tesque), and 2% HEPES (Life Technologies, 
USA). Cells were maintained with 5 µg/ml of Plasmocin (Invivogen, USA) to prevent 
mycoplasma infection.  
2.2 Reagents 
Cytarabine (Ara-C) was purchased from (Wako Chemicals, Japan). RNA 
POL III inhibitor, ML-60218 was purchased from Calbiochem (Japan). Both Ara-C 
and ML-60218 were dissolved in DMSO. ATM inhibitor, KU60019 (Tocris 
Bioscience, United Kingdom) and ATR inhibitor, VE821 (Axon Med Chem, 
Netherlands) were used at 10 µM. PicoGreen dsDNA reagent (Life Technologies, 
USA) was used at a 1:100 dilution. Mitotracker (Life Technologies) was dissolved in 
DMSO and used at 500 nM. Fixed cells were treated with 0.5 U/ml recombinant 
RNase H (NEB, USA) for 3 hrs at 37°C. 
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2.3 Immunocytochemistry 
Cells were fixed with 4% paraformaldehyde for 10 min, and permeabilized in 
0.2% Triton X-100 for 15 min. Non-specific sites were blocked with 2% goat serum 
and 1% BSA in 0.2% Triton X-100 for 1 h. Transfected cells were stained with anti-
COX IV antibody (ab16056, Abcam, United Kingdom), anti-POLR3G (LS-C163858, 
LS Bio, USA), or anti-DDX17 (19910-1-AP, Proteintech, USA). The RNA:DNA 
hybrid-specific S9.6 antibody was a kind gift of Dr. D. Koshland, University of 
California, Berkeley (Boguslawski et al., 1986). Secondary polyclonal antibodies 
used were Alexa Fluor AF488 F(ab')2 Fragment of Goat Anti-Mouse IgG (H+L) 
(Life Technologies) and Alexa Fluor AF555 F(ab')2 Fragment of Goat Anti-Rabbit 
IgG (H+L) (Life Technologies). PicoGreen staining of DNA and MitoTracker Red 
CM-H2XRos staining of mitochondria were performed according to the 
manufacturer’s instructions (Life Technologies). Cells were stained with 2 µg/ml of 
Hoechst for 10 min and mounted in mounting medium (Dako, USA). Cell images 
were taken with a Leica TCS SP2 laser confocal scanning microscope (LCSM), and 
analyzed using Volocity (Version 6.2.1) and Imaris. Micrographs showed cells 
representative of total cell populations. 
2.4 Electron microscopy 
Cells were fixed in 4% paraformaldehyde buffered in 0.1 PB at 4°C 
overnight, dehydrated with ethanol before sectioned into 100nm-thin sections. 
Sections were first treated with RNase A for 1 hr, at 37°C, stained with 10 µg/ml of 
dsDNA antibody, before binding to mouse IgG conjugated with 50 nm colloidal gold 
particles (GE Healthcare). For immunogold labeling, cells were fixed in 2% 
glutaraldehyde in PBS at 4°C overnight, and in subsequently in 1% osmium tetroxide. 




96-well polystyrene plates were blocked with 1% BSA for 1 hr and 
subsequently coated with 2, 5, or 10 µg/ml of calf thymus DNA, Poly A:U, Poly G:C 
or Poly I:C in 25 µl PBS buffer for 18 hrs at 4°C. Some wells were treated with 1 
mg/ml DNase I (Roche) for 1 hr. After washing with 0.1% Tween-20 PBS, anti-
dsDNA antibody (Millipore), or anti-dsDNA antibody pre- incubated for 30 min with 
calf thymus DNA was added in triplicates and incubated for 1 hr at 37°C followed by 
goat anti-mouse IgG3-HRP (Southern Biotech) for 1 hr at 37°C. The reaction was 
visualized by TMB Microwell Peroxidase Substrate System (KPL). IFNβ 
concentration in the supernatant of treated cells were measured according to the 
manufacturer’s instructions (PBL InterferonSource).  
2.6 Immunoblot 
Cells were lysed in cold RIPA buffer (Nacalai Tesque) and lysates were 
electrophoresed in 4-12% NuPAGE Bis-Tris gel (Life Technologies) before blotted 
onto PVDF membranes. Antibodies specific to DDX17 (sc-86409, Santa Cruz, USA), 
AGO2 (C34C6, Cell Signaling Technology, USA), and GAPDH (M171-3, MBL), 
and horseradish peroxidase-conjugated secondary antibodies (Cell Signaling 
Technology) were used to develop the blots, with Immobilon Western 
Chemiluminescent HRP Substrate (Milipore, Germany). Digital images were 
acquired using ImageQuant LAS 500 (GE Healthcare, United Kingdom). 
2.7 Immunoprecipitation and mass spectrometry 
2 x 106 A549 cells were seeded into 100-mm dishes and fixed in 1% 
paraformaldehyde (Nacalai Tesque) for 10 min, followed by treatment with 125 mM 
of Glycine (Wako, Japan) for 5 min. Cells were fractionated using MitoSciences cell 
fractionation kit (MS861, Mitosciences, USA). The cytosolic fraction was precleared 
by incubation with 5 µl of Protein G–Sepharose beads (GE Healthcare) at 4°C for 20 
min on a rolling shaker. The cleared supernatant was incubated at 4°C overnight on a 
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rolling shaker with 10 µg/ml of RNA:DNA hybrid antibody and 10 µl of Protein G–
Sepharose beads. Immunoprecipitates were washed subsequently with RIPA buffer, 
low salt buffer (20 mM Tris-HCL pH 8.1, 150 mM NaCl, 0.1% SDS, 1% Triton X-
100, 2mM EDTA), high salt buffer (20 mM Tris-HCL pH 8.1, 600 mM NaCl, 0.1% 
SDS, 1% Triton X-100, 2mM EDTA), final wash (20 mM Tris-HCL pH 8.0, 0.1% 
SDS, 1% Triton X-100, 1 mM EDTA) and TE buffer. Beads were resuspended in TE 
buffer with 1% SDS and incubated at 65°C overnight to release protein complexes for 
subsequent gel electrophoresis. For mass spectrometry, similarly processed cell 
lysates were immunoprecipitated with RNA:DNA hybrid antibody, and silver stained 
using Silver Stain Plus Kit (Bio-Rad, USA) according to the manufacturer’s 
instruction. Bands of interest were cut out and sent for mass spectrometry analysis at 
the Osaka University mass spectrometry facility. 
2.8 Transfection 
A549 cells were transfected with siRNA of DDX17 or POLR3G (Qiagen, 
Netherlands) using LipoFectamine 2000 (Invitrogen) according to manufacturer’s 
instructions. AllStars Negative Control siRNA (Qiagen) was used as a control 
transfection and the sequence was proprietary. The siDDX17 sequences used were: 
siDDX17#1, 5’-CTGGAGTGCATTTGATAGTTA-3’, siDDX17#2, 5’-CGGGATCG 
TAGTGAAACCGAT-3’, and siDDX17#3, 5’-CAGATCTGATATGGGACTATT-3’. 
The siPOLR3G sequences used were: siPOLR3G#1, 5’-AAGGCACACCACTCACT 
AATA-3’ and siPOLR3G#2, 5’-TTGCGGTTGATAATTAACATA-3’. 
2.9 MiRNA microarray analysis 
A549 cells were treated with 10 µM of RNA POL III inhibitor for 24 hrs, or 
subsequently treated with 10 µM of cytarabine or DMSO for 15 hrs. DMSO-treated 
cells served as a control. Total RNA was extracted by Trizol (Life Technologies) and 
labeled using a 3D-Gene miRNA labeling kit. The labeled RNA was hybridized to a 
human miRNA V19 microarray chip containing 2019 miRNA probes and analyzed 
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on a ProScanArray™ microarray scanner (Toray Industries, Japan). MiRNA profiles 
from two pairs of experiments (DMSO, and RNA POL III inhibitor-treatment 
conditions with and without Ara-C each) were provided as sample-wise median-
normalized data by Toray. Data from these four profiles were further normalized 
using all-sample quantile normalization protocol using the corresponding 
Bioconductor package developed by Bolstad et al. (Bolstad et al., 2003). Original 
miRNA profiles consisted of 2019 miRNA probes, of which only a small fraction 
showed significant expression in any of these experiments. After replacing the 
missing valued data (no expression observed) by the minimum of all observed 
expression values, miRNA probes that showed at least 3-fold differential expression 
between any pair of 4 experiments, were used for further quantitative analysis. 
Identified miRNA sequences were used to obtain predicted gene targets, as acquired 
from public domain resource, mir-DIANA (Vlachos et al., 2012). A P-value 
threshold of 0.05 and MicroT threshold of 0.8 was applied. 
2.10 Quantitative PCR 
Total RNA was isolated using the RNeasy kit (Qiagen, Netherlands). Real-
time PCR assays were performed using an Applied Biosystems 7500 sequence 
detector. 2 µg of total RNA was reverse transcribed to cDNA using random hexamers 
and a SuperScript II First-Strand Synthesis System (Invitrogen, USA). Each 
amplification mixture (25 µl) contained 25 ng of reverse-transcribed RNA, 8 mM 
forward primer, 8 mM reverse primer and 12.5 µl of iTaq SYBR Green Supermix 
with ROX (Bio-Rad). PCR thermocycling parameters were 50°C for 2 min, 95°C for 
10 min, and 40 cycles of 95°C for 15s, 60°C for 15s and 72°C for 1 min. All samples 
were normalized to the signal generated from the housekeeping gene HPRT1. SYBR 
green PCR was performed in triplicate. The following primers were used: XPO1-5’, 
5’-AGGTTGGAGAAGTGATGCCA-3’; XPO1-3’, 5’-GCACCAATCATGTACCCC 
AC-3’; KPNB1-5’, 5’-GACCGACTACCCAGACAGAG-3’; KPNB1-3’, 5’-GACTC 
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CTCCTAAGACGACGG-3’; NUP153-5’, 5’-GCCCAAATCTTCCTCTGCAG-3’; 
NUP153-3’, 5’-GAAAGGAGCCACTGAAGCAC-3’; HPRT1-5’, 5’-CCCTGGCGT 
CGTGATTAGTG-3’; HPRT1-3’, 5’-TCGAGCAAGACGTTCAGTCC-3’. Samples 
prepared without reverse transcription served as negative control templates. 
2.11 Flow cytometry 
Blood from mice was collected by facial bleeding and red blood cells were 
removed by red blood cell lysis. Fc receptors on blood cells were blocked by 
incubating cells with CD16/CD32-specific antibodies for 15 min (eBioscience, USA). 
Tumor cells were stained with B220-APC (clone RA3-6B2; eBioscience) and 
Immunoglobulin M (IgM)-FITC (clone RMM-1, BioLegend, USA). Staining of cells 
was analyzed using a BS LSRII (BD Biosciences, USA) and FlowJo. 8.8.7 (TreeStar, 
USA). Tumor load was calculated as follows: Σ (% IgM−B220low) × % B220++ 
(IgM+B220low) × % B220+. 
2.12 Statistical Analysis 
For statistical analysis, one-tailed Student’s t-test (P<0.05) was used unless 
otherwise stated, after data were tested positive for normality by Shapiro-Wilk test. 
For data that failed normality test, non-parametric Mann-Whitney Wilcoxon Rank-
Sum test was used. Error bars represent standard error unless otherwise stated in the 
figure legends. Mice survival data were analyzed using the Log-rank test and by 
Gehan-Breslow-Wilcoxon test (specific statistical analysis for comparison of survival 
data). Results that were statistically significant with a P-value of < 0.05 were 








Chapter 3: Presence of DNA in the Cytosol in response to DNA 
damage 
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3.1 Presence of cytosolic DNA in cell lines 
Genomic DNA normally locates in the cell within the nucleus or 
mitochondria, while some retroelements locate in the cytosol (Rush and Misra, 1985). 
However, genomic stability in cancer cells with DNA breaks may cause the presence 
of delocalized nucleic acids. Previously, Lam et al., used dsDNA antibodies to stain 
for the presence of dsDNA in Eµ-Myc derived murine tumor cells (Lam et al., 
2014a). It was hypothesized that presence of dsDNA was associated with 
tumorigenesis of cancer cells, since dsDNA had been previously shown to trigger an 
antiviral immune response (Ishii et al., 2006).  
 We first confirmed the specificity of the cytosolic DNA antibody with a 
series of DNA ELISA titrations. dsDNA antibody had a high affinity to calf thymus 
(CT) dsDNA, and competitive inhibition from increasing concentrations of free CT-
DNA decreased binding affinity of dsDNA antibody (Fig. 3.1a). DNase I treatment of 
coated DNA before incubation with dsDNA antibodies abrogated the binding affinity 
of the dsDNA antibody, suggesting the presence of DNA being removed by DNase I 
treatment and hence antibody binding. CT DNA showed the highest affinity for 
dsDNA antibody as compared to other synthetic polynucleotides, and Poly I:C, a 
synthetic analog of dsRNA (Fig. 3.1b). IgG3 anti-mouse antibody was used as a 
control to the dsDNA antibody, and showed no observable binding to CT DNA (Fig. 
3.1c). 
Figure 3.1 Specificity of dsDNA antibodies. Anti-dsDNA mouse monoclonal 
antibody preferentially recognizes ds-nucleotides. ELISA plates were coated with 
indicated amounts of calf thymus DNA 94. Coated plates were incubated with 
dsDNA-specific antibody (a, b, c) or isotype control antibody (c). As a control, some 
wells were incubated in the presence of (a) calf thymus DNA (CT), DNase I, or (b) 
Poly G:C, Poly A:U, Poly I:C. Specific antibody staining was visualized by ELISA.  
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To determine if cytosolic dsDNA was also present in tumor cells, various 
human cell lines were stained with anti-dsDNA antibodies. Fluorescent microscopy 
confirmed the presence of cytosolic dsDNA (Fig. 3.2), congruent with observance of 
cytosolic dsDNA present in murine tumor cells. To exclude double-stranded 
mitochondria DNA, cells were co-stained with COX IV, a mitochondrial membrane 
protein. Further, cloning and sequencing of the DNA revealed nuclear repetitive 
sequences (Shen et al. manuscript under revision) indicative of DNA fragments 
originating from nucleus.  
To characterize the staining location of dsDNA, MRC-5 cells, which had a 
relatively large cytoplasmic area for visualization, were immunogold labeled using 
dsDNA antibodies, and viewed with electron microscopy. Fixed cells were pre-
treated with RNase A to remove unspecific dsRNA staining. Comparing against the 
isotype antibody, significant staining of the cytoplasm and nucleus was observed with 
dsDNA antibodies, visualized as black circular particles (Fig. 3.3). However, the 
dsDNA did not concentrate at a particular organelle or surface membrane, suggesting 
the presence of dsDNA in the cytosol independent of compartmental organelles. 
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Figure 3.2 Presence of cytosolic DNA in various cell lines. The human lung 
carcinoma cell line A549 and human lung tissue derived cell line MRC-5 was stained 
with dsDNA-specific antibodies (Red), COX IV-specific antibodies (Green), and 
DAPI (Blue).  
 
 
Figure 3.3 Staining of cytosolic dsDNA in MRC-5 cells. MRC-5 cells were pre-
treated with RNase A, fixed and sectioned before staining by immunogold labeled 
dsDNA antibodies. These were visualized as black circular particles throughout the 
cell under transmission electron microscopy. Representative black particles were 
indicated by white arrows. Scale bars represent 10 µm.  
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3.2 DNA damage increases level of cytosolic DNA  
To investigate the effect of DNA damage on cytosolic DNA, A549 cells were 
treated with cytarabine (Ara-C). Ara-C is a chemotherapy drug commonly used in 
leukemias such as acute myeloid leukemia (AML) and non-Hodgkin lymphoma was 
used to treat cells (Wiernik et al., 1989). Ara-C damages DNA by interfering with 
DNA synthesis during the S phase of cell replication, exhibiting anti-metabolic 
activity by mainly masquerading as a pyramidine (cytosine arabinoside triphosphate) 
for incorporation into the extending DNA strand (Jamieson et al., 1990; Gmeiner et 
al., 1998). Previous treatment kinetics studies with Ara-C suggested IRF3 
phosphorylation for interferon response occurred by 15 hrs of Ara-C treatment (Lam 
et al., 2014a). To determine if similar kinetics might occur with cytosolic DNA 
accumulation after DNA damage, cytosolic dsDNA was quantified using a Qubit 
assay, normalizing dsDNA concentration to overall protein levels. This assay uses a 
dsDNA dye that only fluoresces when bound to DNA, and fluorescence is read via a 
fluorometer. With a time-course treatment of Ara-C from 0-15 hrs, increasing 
concentration of dsDNA was detected in cytosolic fractions by Qubit assay, while 
dsDNA concentration in nuclear fractions did not increase significantly (Fig. 3.4a). 
At 24 hrs, cells could be going through apoptosis due to high toxicity of Ara-C over 
an extended period of time, thus the dsDNA might be fragmented and removed from 
the cell. To assess purity of samples, a western blot of each fraction was run and 
stained with cytosolic and nuclear protein markers, which indicated the existence of 
dsDNA in the pure cytosolic fraction (Fig. 3.4b). 
To visualize this increase of cytosolic dsDNA, cells were first treated with 
Ara-C before dsDNA antibody or PicoGreen staining. DMSO treatment was used as a 
negative control, since DMSO was used as a solvent for Ara-C. PicoGreen is a DNA 
staining dye that intercalates double strand DNA and also interacts with the minor 
groove of DNA (Dragan et al., 2010). In addition, p-ATM was co-stained to detect 
 47 
for the occurrence of the DDR in response to damage, which activates downstream 
effector molecules through phosphorylation. ATM (ataxia talengiectasia mutated) is 
phosphorylated at Ser 1981 in response to DNA damage, which stabilizes ATM to 
provide its activation of kinase activity to initiate a proper DNA damage response (So 
et al., 2009). Increased p-ATM nuclear staining of cells after treatment with Ara-C 
indicated cellular DNA damage (Fig. 3.5a).  
Similar to the Qubit assay, presence of dsDNA in the cytosol increased with 
DNA damage, as shown by increased cytosolic staining by dsDNA antibody (Fig. 
3.5, a and c), and PicoGreen (Fig. 3.5, b and d) in cells after Ara-C treatment. In 
addition, other cell lines such as LOVO and HCT116 colorectal adenocarcinoma also 
show similar cytosolic DNA staining (Shen et al., manuscript in preparation). These 
data collectively indicate the importance of DNA damage for cytosolic dsDNA 
accumulation in human tumor cells. 
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Figure 3.4 Cytosolic DNA increased in response to DNA damage. (a) A549 cells 
were treated with DMSO or 10 µM Ara-C for increasing periods of time (0, 6, 15, 24 
hrs). Cells were then fractionated into nuclear and cytosolic fractions. dsDNA and 
protein concentration was measured using the Qubit assay. Data were plotted with 
(mean ± SEM), * P < 0.05. (b) A portion of the obtained fractions from (a) were used 
for immunoblotting, and staining with antibodies against GAPDH and histone H2A.   
 
 
 Figure 3.5 Presence of cytosolic DNA increases after DNA damage with Ara-C. 
A549 cells were either treated with DMSO or 10 µM of Ara-C for 15 hrs. (a) Cells 
were stained for marker of DDR p-ATM (Red), dsDNA antibodies (Green), and 
Hoechst (Blue). (b) Cells were stained with 10 µl/ml of the vital dsDNA-specific dye 
PicoGreen (Green) for 1 hr. (c and d) Quantification of cytosolic dsDNA antibody 
stain intensity in (a) and cytosolic PicoGreen stain intensity in (b) respectively. Data 
were plotted with (mean ± SEM), * P < 0.05.  
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3.3 Accumulation of dsDNA by DNA damage depends on ATM 
DNA damage response involves p53 activation with the phosphorylation of 
ATM or ATR that activates Chk1. To examine the regulation of dsDNA by DNA 
damage, A549 cells were treated with an ATM/ATR inhibitor, caffeine, for 
increasing periods of time, and cytosolic dsDNA accumulation disappeared after up 
to 24 hrs of treatment (Fig. 3.6, a and c). This ATM/ATR-dependent inhibition was 
also seen in another cell line THP-1, derived from an acute monocytic leukemia 
patient (Fig. 3.6b). The same dsDNA antibody was used for staining of Fig. 4.6a and 
b, and only the secondary antibody conjugated to different fluorophores (AF488 for 
green and AF549 for red), thus the stain colours would not account for the variation 
in staining intensities in different cells over a period of time. Taken together, this 
demonstrated that the accumulation of dsDNA was dependent upon DNA damage 
response mechanisms, and further attributes the occurrence of cytosolic dsDNA to the 
presence of DNA damage within the genome. 
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Figure 3.6 Cytosolic dsDNA disappeared after treatment with ATM/ATR 
inhibitor. (a) A549 cells were treated with 7.7 mM of ATM/ATR inhibitor, caffeine, 
for increasing periods of time (0, 16, 24 hrs), before being fixed and stained for 
dsDNA (Red), and Hoechst (Blue). (b) THP-1 cells were treated with 7.7 mM of 
ATM/ATR inhibitor, caffeine, for 15 hrs, before being fixed and stained for dsDNA 
(Green), and Hoechst (Blue). (c) Quantification of dsDNA stain in (a). Data were 
plotted as (mean ± SEM). * P < 0.05. 
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3.4 Cytosolic DNA does not colocalize with known DNA-binding molecules 
To assess the significance of cytosolic DNA in DNA sensing, we examined 
the localization of cytosolic DNA-binding proteins with respect to cytosolic DNA.  
The antibodies were used in immunofluorescence staining with known cellular 
molecules to observe for colocalization.    
 HMGB1 is a DNA-binding protein involved in TLR9 signaling of CpG 
dsDNA in the cytosol (Ivanov et al., 2007). In particular, HMGB1 is associated with 
DNA damage sensing, and was found to mediate the kinetics of p53 phosphorylation 
after Ara-C genotoxic agent exposure (Krynetskaia et al., 2009). Knockout mice 
studies of HMGB1 have shown defects in type 1 interferon and cytokine production 
(Yanai et al., 2009). We stained for HMGB1 along with dsDNA in MRC-5 cells, 
however HMGB1 was localized mainly in the nucleus, supporting previous reports of 
HMGB1 as a nuclear protein (Fig. 3.7).  
DNA sensing also requires STING as a common modulator in many sensing 
pathways (Nakhaei et al., 2010; Barber, 2014). STING has been suggested to localize 
to the mitochondria membrane, and moves to the endosome once activated. STING is 
able to bind cyclic-dinucleotides directly, and also functions as an indirect modulator 
of many dsDNA sensors, such as DDX41, IFI16, and cyclic GMP-AMP (cGAS) 
(Unterholzner et al., 2010; Zhang et al., 2011c; Lam et al., 2014b). A possibility that 
cytosolic dsDNA could bind STING led us to co-stain dsDNA with STING. 
However, majority of the dsDNA did not colocalize with STING proteins in the 
cytosol (Fig. 3.7). 
KU80 is a NHEJ complex protein that forms a heterodimeric complex with 
KU70, which has been purported to be a cytosolic DNA sensor that triggers type III 
interferon response to dsDNA (Zhang et al., 2011a). Co-stain of KU80 with dsDNA 
in A549 cells showed that while KU80 had a mainly nuclear stain, there was a 
substantial cytosolic stain that did not colocalize with the cytosolic dsDNA antibody, 
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suggesting that the DNA repair DNA sensor KU70/80 in the cytosol was not bound to 
cytosolic dsDNA (Fig. 3.7). 
Collectively, our data suggested that dsDNA was unable to be recognized by 
above-mentioned dsDNA sensors, raising the question whether cytosolic dsDNA in 
these human cell lines are able to invoke an innate immune response. 
 
 
Figure 3.7 Cytosolic DNA partially colocalizes with DNA sensor molecules. A549 
or MRC-5 cells were costained for dsDNA (Red), (a) HMGB1, (b) STING or (c) 
KU80 antibodies (Green) respectively, and Hoechst (Blue). 
 
 In addition to conventional DNA sensor proteins, histone H2B was identified 
to have anti-viral properties, as extrachromosomal histone H2B depletion resulted in 
decreased IFN-β production in HEK293 cells in response to dsDNA, and affected 
DNA virus replication (Kobiyama et al., 2010). In particular, histone H2B is found 
both in the nucleus and cytoplasm, making it a possible candidate for the regulation 
of the cytosolic dsDNA. We also stained for additional histones in addition to H2B to 
detect for colocalization of dsDNA, namely H2A, H3, H3 (citrulline), and H4 (Fig. 
3.8). In particular, nucleolar staining for some histones was also observed, 
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representative of chromatin regions in the eukaryotic cells in conjunction with 
chromosome unwinding from histones at sites of active transcription (Musinova et 
al., 2011). H3 (citrulline) antibodies were used to stain citrullinated H3 proteins, as 
this posttranslational modification induced chromatin decondensation, which may 
interfere with transcription (Wang et al., 2009; Sharma et al., 2012). However, no 
distinct cytosolic stain was observed for any of the histone proteins. 
 
Figure 3.8 Cytosolic dsDNA does not colocalize with histone proteins. (a) MRC-5 
cells were costained for histone proteins H2A, H2B, H3, H3 cit and H4 (Green), 




To investigate if cytosolic DNA was located within organelles or complexes 
in the cell cytoplasm that might be less visible in prior electron microscopy 
experiments, we identified organelles that were associated with immune signaling or 
recognition of antigens. Exosomes are thought to promote immune responses (Anand, 
2010; Bretz et al., 2013). Recently, exosomal dsDNA (exoDNA) was found in tumor-
derived exosomes, and exoDNA sequences were reflective of nuclear genomic 
regions, although lower amounts of exoDNA were observed in lung cancer cell lines 
(Thakur et al., 2014). However, when we stained CD63, a known exosome marker, 
with dsDNA in MRC-5 lung-derived cells, we did not see significant costaining of 
the two (Fig. 3.9), suggesting a lack of interaction of dsDNA with exosomes. 
Stress granules are cytoplasmic compartments that form in response to 
various types of stress (Tourriere et al., 2003; Gao et al., 2010). They contain RNA 
released from disrupted polysomes in response to stress, which stalls the translation 
process. Stress granule formation has also been thought to module the DNA damage 
response (Pothof et al., 2009), providing a possibility that damage DNA might also 
associate with stress granules. Further, antiviral stress granules containing RIG-1 
have been characterized (Onomoto et al., 2012) after influenza A virus cellular 
infection. RIG-1 is a critical sensor of viral RNA that triggers the IPS-1 pathway to 
activate interferon-stimulated genes (Kawai et al., 2005). We stained for G3BP1, a 
marker protein found in the stress granule complex, with dsDNA, however there was 
little colocalization of dsDNA cytosolic clusters and G3BP1 in MRC-5 cells (Fig. 
3.9). 
 Autophagy is known to degrade damaged organelles and proteins, especially 
in cell starvation or damage (Mizushima, 2007). DNA damage also triggers 
autophagy, which might be an alternative route for a damaged cell, as opposed to 
apoptosis (Rodriguez-Rocha et al., 2011). LC3B is a constituent of the 
autophagosome complex that forms as part of the autophagy process in the cytosol. 
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While we co-stained for LC3B and dsDNA, there was also no evidence for 
colocalization, suggesting that autophagy might not be involved in dsDNA 
accumulation in the cell (Fig. 3.9).  
 
 
Figure 3.9 Cytosolic dsDNA does not colocalize with major compartmental 
proteins. MRC-5 cells were costained with antibodies specific against compartmental 
proteins CD63, G3BP1, and LC3B (Green) and dsDNA (Red) antibodies, followed 
by Hoechst (Blue).  
 
3.5 DDX17 expression decreases with DNA damage 
To investigate proteins involved in dsDNA binding, the cytosolic fraction of 
A549 cells was immunoprecipitated with dsDNA antibody and silver staining was 
performed on the SDS-PAGE gel. The immunoprecipitation was also performed with 
RNase H treatment, as RNase H is an enzyme that removes RNA:DNA hybrid 
specific interactions (Nowotny et al., 2008; Rychlik et al., 2010). A band of interest 
was identified by its disappearance after RNase H treatment (Fig. 3.10), as binding of 
these proteins to the dsDNA antibody would be sensitive to nucleic acid degradation. 
Mass spectrometry analysis of the cut band at 80 kDa revealed a list of potential 
proteins, of which one of the genes of interest was DEAD (Asp-Glu-Ala-Asp) Box 
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Helicase 17 (DDX17), a 72 kDa helicase protein. Further, DDX17 was identified to 
play a role in cell proliferation leading to cell survival. The possibility that cytosolic 
DNA could influence cell survival via the effect of cytosolic DNA led us to 
investigate the role of DDX17 in DNA damage.  
 
 
Figure 3.10 DDX17 potentially binds cytosolic dsDNA. A549 cells were 
fractionated and cytosolic fractions were immunoprecipitated with dsDNA antibody 
before RNase H or buffer treatment and subsequently SDS-PAGE analysis (Lane 1 
and 3). The gel was silver-stained and the band of interest (white arrow) was sent for 
mass spectrometry analysis. Lane 2 and 4 were the final washes after elution of the 
protein to ensure that no protein remained on the beads. Lane 5 and 6 contained the 
fractionated A549 nuclear and cytosolic lysate respectively. 
 
 
DNA damage is known to phosphorylate DDX17, possibly via ATM/ATR 
induction (Matsuoka et al., 2007; Wang and Taniguchi, 2013). DDX5 was also 
shown to activate transcription factors such as Era, p53, and beta-catenin (Germann et 
al., 2012). In addition to transcriptional regulation, DDX17 is known to be part of the 
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microRNA machinery in the nucleus, recognizing pre-miRNA seeded for export to 
the cytoplasm (Wang and Taniguchi, 2013).  However, its specific role in miRNA 
regulation for tumorigenesis has yet to be elucidated (van Kouwenhove et al., 2011). 
Nevertheless, DNA damage has been shown to regulate pre-miRNA export from the 
nucleus for miRNA processing in an ATM/Akt-dependent manner (Wan et al., 2013).  
To visualize the localization of DDX17, we stained A549 cells for DDX17 
along with dsDNA. Majority of DDX17 accumulated in the nucleus (Fig. 3.11), 
consistent with the fact that DDX17 is a nuclear protein required in Drosha complex 
formation for miRNA biogenesis (Fukuda et al., 2007). However, cytosolic DDX17 
was present in cells, and upon treatment of DNA damage agent Ara-C, cytosolic 
DDX17 amounts were increased. This suggested that DDX17 could play a role in 





Figure 3.11 DDX17 is partially localized to the cytosol in response to DNA 
damage. (a) A549 cells were treated with DMSO or 10 µM of Ara-C for 15 hrs. Cells 
were stained with antibodies against DDX17 (Red), dsDNA (Green), and Hoechst 
(Blue). (b) Relative quantification of cytosolic DDX17 in (a). Two-tailed Wilcoxon 
test was performed. Error bars represent SEM. * P < 0.05. 
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3.6 DDX17 expression regulates the presence of cytosolic dsDNA  
To assess if DDX17 may affect presence of cytosolic DNA, control or 
DDX17 siRNA was transfected into cells, and fixed microscopy slides were treated 
with RNase A to remove unspecific double stranded RNA staining from siRNA. 
Negative control siRNA, a scrambled siRNA sequence determined not to target any 
gene, was used to controlled off-target effects of siRNA. Cells transfected with 
negative control siRNA were stained in the column labeled ‘Control’ and used for 
comparison of siDDX17. siRNA was transfected at a low concentration of 20 nM to 
reduce off-target effects that would be seen when cells are transfected at higher 
siRNA concentrations (>100 nM) (Semizarov et al., 2003). Out of three siDDX17 
sequences, siDDX17 #3 had the highest knockdown efficiency as observed by 
immunoblot (Fig. 3.12a). Immunofluorescence showed that knockdown of DDX17 
resulted in increased cytosolic DNA in A549 cells (Fig. 3.12b), suggesting that 




Figure 3.12 DDX17 knockdown increased the levels of cytosolic DNA (a) A549 
cells were transfected with 20 nM of control scrambled siRNA, or siDDX17 (#1, #2, 
#3). Cells were re-transfected with 20 nM of the same siRNA after 48 hrs to ensure 
sufficient knockdown. A portion of the transfected cells was used for immunoblot 
analysis of protein knockdown of DDX17. GAPDH was used as a loading control. (b) 
Cells were harvested two days after the second transfection for immunofluorescence 
staining using antibodies specific against DDX17 (Red), dsDNA (Green), and 







Chapter 4: RNA:DNA hybrids in cytosolic abundance 
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4.1 Presence of RNA:DNA hybrids in cytosol 
Lam et al previously stained for the presence of cytosolic DNA in murine 
tumor cells (Lam et al., 2014a). Intriguingly, PicoGreen, the vital dye that was used 
in the detection of dsDNA (Ashley et al., 2005; Dragan et al., 2010), was also 
purported to detect RNA:DNA hybrids, as it also stains dsRNA with ten-fold lower 
intensity (Singer et al., 1997). In an effort to characterize cytosolic DNA and the 
possibility of RNA:DNA hybrids in cells, the accumulation of cytosolic nucleic acids 
in various cells was investigated.  PicoGreen staining in A549 human lung carcinoma 
cell line showed the presence of extranuclear nucleotides (Fig. 4.1, a and b).  
To further substantiate the specificity of RNA:DNA hybrid staining, some 
cells were treated with RNase H, an endoribonuclease that specifically degrades RNA 
in RNA:DNA hybrids (Frank et al., 1994). S9.6 is a monoclonal antibody specific to 
RNA:DNA hybrids (Boguslawski et al., 1986; Hu et al., 2006). Both PicoGreen and 
S9.6 signals were decreased, supporting the fact that RNA:DNA hybrids are 
constitutively present in the tested cell lines (Fig. 4.1). As RNA:DNA hybrids can 
also form during replication of mitochondrial DNA, cells were stained with the 
mitochondrial marker COX IV or Mitotracker. 3D rendering of the confocal images 
showed that the detected RNA:DNA hybrids are localized outside of mitochondria 
(Fig. 4.1, b and e). 
Apart from previous findings that RNA:DNA hybrids can form in the cytosol 
of retrovirus infected cells (Whitcomb and Hughes, 1992), I found the first instance 
of extranuclear RNA:DNA hybrids present in many uninfected cell lines, as detected 
by the antibody S9.6. In addition to the A549 cell line, cell lines of human cancer cell 
lines derived from colorectal carcinoma (LoVo, HCT 116, HT29), acute monocytic 
leukemia (THP-1), and normal lung tissue MRC-5 (Fig. 4.2a) were also stained. 
Some cell lines were also stained by PicoGreen for extranuclear nucleotides, which 
include RNA:DNA hybrids and may also contain dsDNA (Fig. 4.2b). 
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In summary, I found that RNA:DNA hybrids are constitutively present in the 
cytosol of the human cells. 
 
 
Figure 4.1 Presence of RNA:DNA hybrids in the cytosol of human lung cancer 
cells. (a) The A549 human lung carcinoma cell line was stained with 10 µl/ml of the 
vital dsDNA-specific dye PicoGreen (Green) for 1 hr and 100 nM of the 
mitochondria-specific vital dye MitoTracker (Red) for 30 minutes. Samples shown in 
lower row were pretreated with 0.5 U/ml of RNase H. (b and c) 3D isosurface 
rendering (b) and quantification (c) of PicoGreen staining in the nucleus and cytosol 
of images shown in (a). One-tailed Wilcoxon test was performed. Error bars represent 
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SEM. * P < 0.05 (d) A549 cells were stained with the RNA:DNA hybrid-specific 
antibody S9.6 (Green) and the mitochondrial marker COX IV (Red) in the presence 
of Hoechst (Blue). Cells shown in the lower row were pretreated with 0.5 U/ml of 
RNase H before staining. (e and f), 3D isosurface rendering (e) and quantification (f) 
of RNA:DNA hybrid staining of images shown in (d). One-tailed Wilcoxon test was 




Figure 4.2 Presence of cytosolic RNA:DNA hybrids in human tumor cell lines. 
(a) The human colorectal carcinoma cell lines LoVo, HCT 116, and HT29, the human 
acute monocytic leukemia cell line THP-1, and the human normal lung tissue derived 
cell line MRC-5, were stained for the presence of RNA:DNA hybrids (Red) and 
Hoechst (Blue). (b) LoVo, HCT116 and HT29 were stained with PicoGreen (Upper 
row). Bright field images (DIC) of cells are shown in the lower row.  
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4.2 Specificity of RNA:DNA hybrids 
In agreement with the observation in Figure 4.1 that PicoGreen stain is 
removed with RNase H treatment, S9.6 staining partially co-stained with PicoGreen 
suggesting that PicoGreen also stains RNA:DNA hybrids in addition to cytosolic 
dsDNA (Fig. 4.3a). Correspondingly, co-stain of cytosolic RNA:DNA hybrids and 
dsDNA also showed partial colocalization (Fig. 4.3b), suggesting partial overlap or 
recognition of these two nucleic acid structures in the cytosol.    
Previously, we found that cytosolic dsDNA depends on the DDR in murine 
cells, and observed the presence of cytosolic dsDNA in murine B-cell lymphoma 
cells (Lam et al., 2014a). To test if the same cellular response to DNA damage is 
required for the presence of cytosolic RNA:DNA hybrids in human cells, ATM and 
ATR, two kinases that initiate the DDR, were inhibited. Strikingly, in contrast to 
cytosolic dsDNA, inhibition of the DDR had no effect on the presence of RNA:DNA 
hybrids in the cytosol (Fig. 4.4). Hence, unlike cytosolic dsDNA, RNA:DNA hybrid 
levels in the cytosol of A549 is not dependent on DDR.  
 
 
Figure 4.3 Specificity of S9.6 antibody for RNA:DNA hybrids. 3D isosurface 
rendering of staining of A549 cells with RNA:DNA hybrid-specific antibodies (Red), 
(a) PicoGreen (Green) or (b) dsDNA antibody (Green), and Hoechst (Blue). 





Figure 4.4 Presence of RNA:DNA hybrid does not depend on the DDR. A549 
cells were treated with 10 µM of ATM inhibitor (ATMi), or ATR inhibitor (ATRi), or 
both for 15 hrs. Cells were stained with RNA:DNA hybrids (Red) in the presence of 
Hoechst (Blue).  Fig. 4.4 kindly contributed by Y.J. Shen. 
 
 
4.3 Inhibition of RNA POL III decreases cytosolic RNA:DNA hybrids 
RNA:DNA hybrids can occur during transcription of DNA (Shaw and Arya, 
2008). To test the role of transcription, A549 cells were treated with RNA POL III 
inhibitors (Wu et al., 2003). The presence of cytosolic RNA:DNA hybrids was 
blocked significantly at doses above the IC50 (half maximal inhibitory concentration) 
of ML-60218 for POL III, which is 27 µM in mammalian cells (Fig. 4.5) (Wu et al., 
2003). POL III inhibition resulted in a significant decrease in cytosolic PicoGreen 
staining while not affecting nuclear PicoGreen intensity (Fig. 4.5b), suggesting that 
PicoGreen also stains large amounts of dsDNA in the nucleus. However, RNA:DNA 
hybrid antibody staining showed significant decrease of nuclear staining of cytosolic 
RNA:DNA hybrids at 30 µM of ML-60218 treatment (Fig. 4.5d), suggesting ML-
60218 treatment also affects nuclear RNA:DNA hybrids. 
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Figure 4.5 The presence of cytosolic RNA:DNA hybrids depends on RNA POL 
III. (a) A549 cells were treated with the indicated concentration of RNA POL III 
inhibitor ML-60218 for 3 hrs, before staining with 10 µl/ml PicoGreen (Green) for 1 
hr and 100 nM of the mitochondria-specific vital dye MitoTracker (Red) for 30 
minutes. (b) Cytosolic and nuclear intensity quantification of images shown in (a). 
Two-tailed Wilcoxon test was performed. Error bars represent SEM. * P < 0.05. (c) 
A549 cells were treated with indicated concentration of RNA POL III inhibitor ML-
60218 for 3 hrs, before staining of cells with RNA:DNA hybrid-specific S9.6 
antibodies (Green) and Hoechst (Blue). (d) Cytosolic and nuclear intensity 
quantification of images shown in (c). Two-tailed Wilcoxon test was performed. 
Error bars represent SEM. * P < 0.05. 
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To further investigate the role of RNA POL III on RNA:DNA hybrids, 
control scrambled siRNA or siPOLR3G (#1, #2), were transfected into A549 cells 
(Fig. 4.6). POLR3G is a subunit of the RNA POL III complex that is involved in 
catalysis of transcription of DNA into RNA (Wang and Roeder, 1997). Strikingly, 
siPOLR3G#1 caused a decrease in POLR3G expression detectable by 
immunofluorescence, which corresponded to diminished levels of cytosolic 
RNA:DNA hybrids. However, siPOLR3G#2 failed to suppress POLR3G expression 
and had little effect on RNA:DNA hybrids.  
To address if POL III contributes to the generation of RNA:DNA hybrids in 
the cytosol, we stained A549 cells for POLR3G, a subunit of the POL III complex. In 
contrast to POL II, which is exclusively localized in the nucleus, a subset of POL III 
is present in the cytosol, where it might act a putative cytosolic DNA sensor (Chiu et 
al., 2009). In A549 cells POLR3G was localized in the nucleus and no significant co-







      
 
Figure 4.6 siPOLR3G abrogated the presence of cytosolic RNA:DNA hybrids. 
A549 cells were transfected with 25 nM of control scrambled sequence siRNA, or 
siRNA against POLR3G (siPOLR3G #1, siPOLR3G #2). Two days after transfection, 
cells were stained for RNA:DNA hybrids (Green), POLR3G (Red), and Hoechst 
(Blue).  
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4.4 Presence of RNA:DNA hybrids is independent of DNA damage   
RNA:DNA hybrids cause stalling of the replication fork and formation of 
dsDNA breaks  (Aguilera and Garcia-Muse, 2012; Chan et al., 2014; Hamperl and 
Cimprich, 2014). To test if stalling of replication forks increases the amount of 
RNA:DNA hybrid in the cytosol, A549 cells were treated with Ara-C and aphidicolin 
(APH), an inhibitor of DNA polymerases (Pedrali-Noy and Spadari, 1979).  
Treatment with Ara-C or APH had no effect on the level of cytosolic 
RNA:DNA hybrids in A549 cells (Fig. 4.7a, c). Moreover, Ara-C treatment did not 
increase the co-localization of POLR3G and RNA:DNA hybrids  (Fig. 4.7a, b). This 
suggested that inhibition of DNA replication and replication fork progression is not 
sufficient to increase the levels of RNA:DNA hybrid in the cytosol. In summary, our 
data suggest that cytosolic RNA:DNA hybrids are generated by RNA POL III activity 
in the nucleus, independent of DNA replication. 
 
4.5 RNA:DNA hybrids are present in human lymphoma tissues 
To extend the findings of RNA:DNA hybrids present in human cells, and 
validate these findings in human tissues, we obtained human normal spleen tissue or 
cancer tissue from a B-cell lymphoma patient. Strikingly, staining of RNA:DNA 
hybrids showed that while no hybrids were detected in normal spleen tissue, the 
cancerous spleen tissue had abundant RNA:DNA hybrid staining (Fig. 4.8). This 




Figure 4.7. Levels of cytosolic RNA:DNA hybrids were not modulated by 
genotoxic replication inhibitors. (a) A549 cells were treated with 10 µM of the 
genotoxic DNA replication inhibitor Ara-C for 15 hrs, and stained RNA:DNA 
hybrids (Green) and POLR3G (Red) in the presence of Hoechst (Blue). (b) A549 
cells treated with Ara-C as in (a) and stained with 10 µl/ml PicoGreen (Green), 
POLR3G-specific antibody (Red), and Hoechst (Blue). (c) A549 cells were treated 
with 4 µM of aphidicolin (APH), an inhibitor of DNA polymerase for 15 hrs, and 
stained with RNA:DNA hybrid-specfic antibody (Green) in the presence of Hoechst 
(Blue). Fig. 4.7c kindly contributed by M. Khatoo. (d) Quantification of cytosolic 
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RNA:DNA hybrid stain in (a). Two-tailed Wilcoxon test was performed. Error bars 
represent SEM.  
 
Figure 4.8 RNA:DNA hybrids are present in human lymphoma tissues. 
Cyrosections of normal human spleen tissue or cancer spleen tissue from a large B 
cell lymphoma patient were stained for RNA:DNA hybrids (Green), marker of B 
cells CD20 (Red), and DAPI (Blue). 
 
 
4.6 Cytosolic RNA:DNA hybrids binds components of the miRNA processing 
machinery  
To determine if RNA:DNA hybrids interact with proteins in the cytosol, we 
performed immunoprecipitation experiments using RNA:DNA hybrid antibodies on 
cytosolic extracts of A549 cells. A fraction of the extracts was treated with RNase H 
before analysis to verify RNA:DNA hybrid-specific binding of proteins. Analysis by 
mass spectrometry identified DDX5/DDX17 and Argonaute (AGO) 2 as proteins that 
immunoprecipitated in a RNA:DNA hybrid-dependent manner (Fig. 4.9). These 
proteins are part of the miRNA processing machinery (Wang and Taniguchi, 2013). 
Immunoblot analyses of immunoprecipitated proteins were consistent with the mass 





Figure 4.9 Immunoprecipitation of cytosolic RNA:DNA hybrids. Cytosolic 
fractions of A549 cells were subjected to immunoprecipitation using RNA:DNA 
hybrid-specific S9.6 antibodies. A part of the cytosolic fraction was pretreated with 
0.5 U/ml RNase H. Immunoprecipitated proteins were detected by SDS-PAGE gel 
electrophoresis and silver staining. Indicated bands were analyzed by mass 
spectrometry. A portion of pretreated cytosolic fraction and nuclear fraction were 
loaded on the two rightmost lanes for comparison.  
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Figure 4.10 Cytosolic RNA:DNA hybrids interact with proteins of the 
microRNA machinery. A549 cells were treated with DMSO or 10 µM Ara-C for 15 
hrs, and harvested for cell fractionation after fixation. Cytosolic fractions were 
subjected to immunoprecipitation with RNA:DNA-specific S9.6 antibodies. 
Immunoblot analysis of immunoprecipitated proteins probed with antibodies specific 






Chapter 5: RNA POL III affects miRNA expression but not 
interferon production 
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5.1 RNA POL III regulates the expression of specific miRNAs  
We sought to gain insights into the RNA POL III-dependent mechanisms 
leading to the presence of cytosolic RNA:DNA hybrids. Our data support the 
possibility that RNA POL III-mediated transcription of miRNAs is associated with 
the generation of RNA:DNA hybrids. As POL III transcribes a subset miRNAs in a 
cell-type-specific manner (Borchert et al., 2006), we determined the RNA POL III-
dependent miRNA expression profile in A549 cells treated with a RNA POL III 
inhibitor or DMSO, subjected to comprehensive miRNA array analysis. To 
distinguish RNA POL III effects from RNA:DNA hybrid-induced DNA damage, 
cells were treated with the genotoxic DNA replication inhibitor Ara-C. A treatment 
time point of 24 hrs was used to ensure sufficient and stable expression of miRNAs 
after the RNA POL III inhibitor treatment, as the inhibitor might disrupt cell division 
if treated for longer periods of time. Results of miRNA expression were normalized 
across all treatment groups and with respect to DMSO treatment.  
A total of 81 differentially expressed miRNA were identified after 
comparison across the treatment groups (Fig. 5.1a). Strikingly, treatment of cells with 
POL III inhibitor resulted in significant downregulation of only four miRNAs: miR-
615-5p, miR-1178-5p, miR-4499, and miR-5571-3p (Fig. 5.1, a and b). The 
expression of miR-615-5p, miR-1178-5p, and miR-5571-3p was also decreased after 
Ara-C treatment, which suggested that these miRNAs were regulated by RNA:DNA 
hybrid-induced DNA damage. In contrast, miR-4499 is likely to be directly 
transcribed by POL III as Ara-C had no effect on its expression. Surprisingly, the 
expression of ten miRNAs was upregulated after treatment with the POL III inhibitor 
ML-60218, but not Ara-C (Fig. 5.1, a and b). In summary, our data indicate that POL 
III regulates the expression of only a number of miRNAs in A549 cells. Hence, it is 
unlikely that cytosolic RNA:DNA hybrids consists of POL III-transcribed 
microRNAs in A549 cells.  
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To test if expression changes in transcripts targeted by POL III-modulated 
miRNAs could account for the presence of cytosolic RNA:DNA, a miRNA target 
prediction and pathway analysis was performed using the DIANA miRPath software 
(http://www.microrna.gr/miRPathv2.) (Vlachos et al., 2012). Among the top ranked 
pathways, RNA transport and RNA surveillance pathways were identified to contain 
predicted genes that are targeted by two or more ML-60218-induced miRNAs (red 
boxes), while other transcripts are potentially targeted by a single miRNA (yellow 
boxes) (Fig. 5.2). Hence, RNA transport or stability may contribute to the presence of 
RNA:DNA hybrids.  
To test the predictability of the DIANA-miRPath software, three genes 
KPNB1, XPO1, and NUP153 were selected for mRNA expression detection after 
RNA POL III inhibition. Gene expression of XPO1 and NUP153 were found to be 
downregulated by 1.6-fold and 3.3-fold respectively, while KPNB1 was not 





Figure 5.1 Dysregulation of microRNAs levels in response to RNA POL III 
inhibition. (a) A549 cells were treated with 10 µM of the RNA POL III inhibitor 
ML-60218 (RPIII inh.) or DMSO for 24 hrs. Some cells were further treated with 
Ara-C for 15 hrs. Heat map of global miRNA expression profile from total RNA 
extracted after treatment is shown. All expression profiles were quantile-normalized 
and then fold values with reference to control (DMSO) were used for plotting this 
heatmap. 81 probes had at least 3-fold differential expression in any pair of 
conditions and were pre-selected for this plot. (b) Scatter-plot of miRNA expression 
profiles between control (DMSO) and ML-6028-treated samples. Decision surface 
was plotted for at least three-fold changes to or from control. Highly upregulated and 
downregulated miRNAs after RPIII inhibitor treatment were identified in the table 




Figure 5.2 RNA transport and mRNA surveillance pathways are potentially 
regulated by RNA POL III modulated miRNAs. List of predicted miRNAs 
regulated by POL III were analyzed for potential gene targets by using online 
resource DIANA-miRPath. Yellow boxes indicate genes that are regulated by one 
miRNA in response to POL III inhibition. The red boxes indicate potential target 
genes regulated by more than one miRNA upon POL III inhibition.  
 
 
Figure 5.3 RNA POL III inhibition decreased mRNA expression of POL III-
regulated miRNA targets. mRNA expression levels of three potential genes, each 
targeted by more than one miRNA. Total RNA was extracted from A549 cells after 
treatment with 10 µM of the RNA POL III inhibitor ML-60218 (RPIII inh.) or DMSO 
for 24 hrs, and subjected to real time PCR analysis. Normalization was done with 
respect to HPRT1 housekeeping gene, and further compared against DMSO-treated 
cells. One-tailed Wilcoxon test was performed. Error bars represent SEM. * P < 0.05. 
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5.2 Interferon-beta levels are refractory to siRNA against RNA POL III  
Another possibility of RNA POL III-directed effects of RNA:DNA hybrids is 
the induction of interferons for innate immune sensing. Previously, transfection of 
poly(dA:dT) was sensed by the cytosolic DNA sensor RNA POL III, and induced 
IFN-β reporter activity (Ablasser et al., 2009). Transfected RNA:DNA hybrids of 60 
base-pairs were also able to induce cytokine and interferon production (Rigby et al., 
2014). Since the presence of cytosolic RNA:DNA hybrids were dependent on RNA 
POL III activity, we blocked RNA POL III activity to determine if RNA:DNA hybrid 
presence could affect interferon expression in tumor cells. Cells were transfected with 
control scrambled siRNA, or siPOLR3G (#1 and #2), for 48 hrs, before analyzed for 
POLR3G knockdown and IFNb mRNA expression. Although knockdown of 
POLR3G, a functional subunit of RNA POL III, was achieved, IFNb expression was 
not diminished in all knockdowns suggesting that siRNA of POLR3G was 
insufficient to dampen IFNb expression (Fig. 5.4).  
To examine chemical inhibition of RNA Pol III on IFNb expression, cells 
were treated with RNA POL III inhibitor ML-60218 before quantitative analysis of 
IFNb. Low concentrations of ML-60218 at 10 µM did not decrease IFNb expression 
(Fig. 5.5). Interestingly, at 30 µM of ML-60218 for 3 hrs, while RNA:DNA hybrids 
were shown to disappear (Fig. 4.5), no observable decrease in IFNb was detected. At 
6 hrs after treatment with 30 µM ML-60218, no significant fold-change decrease of 
IFNb expression was detected, suggesting RNA POL III inhibition did not affect 
IFNβ levels that might be regulated by RNA:DNA sensing. 
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Figure 5.4 siPOLR3G does not regulate IFNb levels. Interferon expression of 
A549 cells in response to siPOLR3G. A549 cells were transfected with 25 nM of 
control scrambled sequence siRNA, or siRNA against POLR3G (siPOLR3G #1, 
siPOLR3G #2). 48 hrs later RNA was extracted to measure mRNA expression of (a) 
POLR3G and (b) IFNb with respect to HPRT1 as a normalization control. One-tailed 
and two-tailed Wilcoxon test was performed for (a) and (b) respectively. Error bars 
represent SEM. * P < 0.05.  
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Figure 5.5 Interferon response was not affected at low levels of chemical RNA 
POL III inhibition. Interferon expression of A549 cells in response to RNA POL III 
inhibition by ML-60218. Cells were either treated with DMSO, or 10 µM, or 30 µM 
of ML-60218, for increasing periods of time (3, 6 hrs). RNA was extracted to 
measure mRNA expression of POLR3G and IFNb with respect to HPRT1 as a 







Chapter 6: Tnfa deficiency reduces survival of Eμ-Myc mice  
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6. Tnfa-deficient Eµ-Myc mice 
The occurrence of cytosolic DNA in tumor cells may lead to the activation of 
the cytosolic DNA sensor pathways, which induces the expression of interferons and 
other pro-inflammatory cytokines (Lam et al., 2014a). Using Eµ-Myc mice, a mouse 
model of spontaneous B cell lymphoma, we found that mice deficient in potential 
cytosolic DNA sensor Zbp1/Dai had higher survival when compared to Zbp1+/+Eμ-
Myc mice (Lam et al., manuscript submitted). We showed that cytosolic DNA 
accumulates in the B cell tumors of Eµ-Myc mice, suggesting that dsDNA increases 
with tumorigenesis. This possibility of dsDNA as a sensor of initial tumor 
development for immune system early recognition, led us to investigate how the 
immune system affects tumor load progression in these mice.  
 
6.1 Decreased survival rate of Tnfa-deficient Eµ-Myc mice 
TBK1 acts as a central transducer node in many signaling pathways of 
immunity (Helgason et al., 2013; Zhao, 2013). It integrates upstream pathogen 
detection, inflammation, or Ras-induced oncogene signals, and depending on adaptor 
recruitment, modulates functions towards immune response, inflammation, and 
processes such as proliferation and autophagy (Helgason et al., 2013). To determine 
if the STING/TBK/IRF3 pathway for interferon signaling (Miyahira et al., 2009; 
Ishikawa and Barber, 2011) is activated during accumulation of cytosolic dsDNA in 
tumor cells, I crossed Eµ-Myc mice with Tnfa/Tbk1-deficient mice. Tbk1-deficient 
mice are embryonic lethal, but can be rescued by Tnfa-deficiency (Perry et al., 2004). 
Wild type littermate controls were also included to minimize differences in 
interpretation of data that might be due to the 129-mixed background of Tnf-/-Tbk1-/- 
mice (Bygrave et al., 2004; Ishii et al., 2006). To exclude the possibility of TNF 
playing a role in the anti-tumor effect by TBK1, I also crossed Tnfa-deficient mice 
with Eµ-Myc mice for comparison. TNF is a known proinflammatory cytokine that 
plays a role in the antitumor response (Carswell et al., 1975). Thus knockout of TNF 
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is hypothesized to reduce the antitumor response in Eµ-Myc mice, leading to lower 
survival due to persistently high tumor load. 
Tnfa+/-Tbk1+/-Eµ-Myc mice have a shorter survival period as compared to 
Tnfa+/+Tbk1+/+Eµ-Myc mice (Fig. 6.1a). Strikingly, Tnfa-/- Tbk1-/-Eµ-Myc mice also 
had shorter survival periods, following a similar survival curve as Tnfa+/-Tbk1+/-Eµ-
Myc mice. Furthermore, Tnfa+/-Eµ-Myc mice also had reduced survival (Fig. 6.1b). 
Similar to a previous report that Tnf heterozygosity affected the levels of TNF by 20 
to 100-fold, and compromised the immune response of mice (Amiot et al., 1997), loss 
of one functional allele of Tnfa was sufficient to observe a phenotypic change in Eµ-
Myc survival. This suggests that TNF acts as a significant pro-inflammatory cytokine 
and actively contributes to the sensing of tumor cells by the immune system, 
irrespective of TBK1 function.  
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Figure 6.1 Survival curve of Eµ-Myc;Tnfa/Tbk1 double-knockout and Eµ-
Myc;Tnfa mice. (a) The survival of mice (from the date of birth until mortality) is 
compared between control Tnfa+/+Tbk1+/+Eµ-Myc (blue curve; n=8), Tnfa+/-Tbk1+/-Eµ-
Myc (red curve; n=15), and Tnfa-/-Tbk1-/-Eµ-Myc knockout mice (black curve; n=11). 
* P < 0.05 by Log-Rank test or by Gehan-Breslow-Wilcoxon Test. (b) Survival curve 
of Eµ-Myc mice deficient in Tnfa. TNF+/-;Eµ-Myc mice (Blue line, n=10) exhibit 
decreased survival compared to TNF+/+;Eµ-Myc mice (Black line, n=7). * P < 0.05 by 
Log-Rank test or by Gehan-Breslow-Wilcoxon Test.  
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6.2 Analysis of Tnfa-deficient Eµ-Myc mice tumor load  
Eµ-Myc mice demonstrate a spontaneous drop in tumor load from day 40 to 
day 60, as assessed by the percentage of B220low tumorigenic B cells in peripheral 
blood (Croxford et al., 2013). This is dependent upon T and NK cells recognition of 
tumor cells. To determine if this antitumor regression phase in Eµ-Myc mice is a 
result of activation of DNA-sensing mechanisms via TBK1, tumor loads of Tnfa-/-
Tbk1-/-Eµ-Myc mice and Tnfa+/-Eµ-Myc mice were characterized. While Tnfa-/-Tbk1-/-
Eµ-Myc and Tnfa+/-Eµ-Myc mice exhibited significant tumor regression of tumor load 
(Fig. 6.2), overall tumor load for Tnfa+/-Eµ-Myc mice was still higher than Eµ-Myc 
mice at all time periods from day 21-60. Further, Tnfa-/-Tbk1-/-Eµ-Myc tumor load 
levels remained low (less than 60%) throughout regression, while Tnfa+/-Eµ-Myc 
tumor load levels were elevated (more than 60%) up to day 50 of mice tumor load 
progression. This suggested that mice with reduced levels of TNF lacked sufficient 
proinflammatory TNF to enhance tumor cell killing, corroborating previous results 
from the survival curve of Tnfa+/-Eµ-Myc mice (Fig. 6.1). Interestingly, the high 
tumor load was diminished in Tnfa-/-Tbk1-/-Eµ-Myc mice, suggesting that 
compensatory immune sensing mechanisms might replace the TBK1-signalling 




Figure 6.2 Tumor load analysis of Eµ-Myc;Tnfa/Tbk1 double-knockout, Eµ-
Myc;Tnfa, and Eµ-Myc mice. The percentage of tumor cells in peripheral blood of 
Tnfa-/-Tbk1-/-Eµ-Myc knockout mice (black squares), or Tnfa+/-Eµ-Myc mice (blank 
squares), or Eµ-Myc mice (black triangles) was determined over a period of day 20 to 
day 65. Data analysed by non-parametric Mann-Whitney Wilcoxon rank-sum test. 
Error bars represent SEM. * over tumor loads represent P < 0.05 compared to 
corresponding tumor load at D21-39. * over drawn lines represent P < 0.05 







Chapter 7: Discussion and future perspectives 
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7.1 Summary of key findings 
In this study, the existence of endogenous nucleic acids in human tumor cells 
was investigated. dsDNA, as well as RNA:DNA hybrids, was found to accumulate in 
the cytosol of a variety of uninfected human cells, including cancer cells. Cytosolic 
dsDNA did not wholly colocalize with histones or other DNA binding proteins. DNA 
damage from exogenous sources triggers the DDR in response to DSB and 
ATM/ATR dependent increase in cytosolic dsDNA that binds to DDX17.  
Conversely, RNA:DNA hybrids are constitutively present in cells and are not 
dependent upon DNA damage or DDR. RNA:DNA hybrid accumulation depends on 
RNA POL III, and RNA:DNA hybrid-binding proteins DDX17 and AGO2 were 
determined through co-immunoprecipitation. These proteins were also involved in 
miRNA processing machinery, providing a possibility of miRNA regulation via 
RNA:DNA hybrid accumulation. RNA POL III-specific miRNAs were identified, 
and target genes of miRNAs included genes coding for proteins in the nuclear pore 
complex and translation, and transcription machinery. Some of these targets were 
downregulated in a similar manner after RNA POL III treatment by real-time PCR, 
suggestive of the cogency of gene target prediction from POL III-specific miRNAs.  
To investigate the role of DNA damage on tumorigenesis, I bred TNF-/-TBK-/- 
mice to Eµ-Myc mice. TNF-/-Eµ-Myc mice alone displayed decreased survival and 
high tumor loads through the regression phase, revealing TNF-α to be an essential 
proinflammatory cytokine for tumor cell killing. The importance of DNA damage in 
tumor cells, and the subsequent cytokine response in Eµ-Myc malignancy thus 
requires TNF-α as a mediator of the immune cell response.  
We proposed a model of RNA:DNA hybrid generation and regulation in 







Figure 7.1 Proposed model of RNA:DNA hybrids and RNA POL III. 
In tumor cells, constant rapid replication of certain genome sequences by RNA POL 
III result in RNA:DNA hybrids that localize in the cytosol of cells, binding to 
DDX17 and AGO2. These structures may be sensed for immune signaling through 
interferons or the inflammasome. RNA POL III also regulates miRNA profile 
expression by inhibiting expression of some miRNAs that target pathways in RNA 
transport and RNA surveillance. RNA:DNA hybrids may also be generated via 
miRNA modulation.  
 93 
 
7.2 dsDNA and RNA:DNA hybrids are derived from two distinct pathways 
The DNA damage pathway has been long associated with interferons and the 
activation of the immune response. Genotoxic stress is a strong precursor of the 
DDR, which is also triggered in infections and cancers. These mechanisms allow a 
distinct regulatory pathway by which the body could discriminate against diseased or 
inflamed tissues or cells. The study of DNA sensors have expanded the field of innate 
immune sensing pathways; however current work in the field focuses on DNA 
sensors against exogenous DAMPs such as viral DNA and RNA present during 
infections.   
Here, my findings show that cytosolic nucleic acids are present constitutively 
in human cancer cell lines, providing another possibility by which DAMPs could be 
generated to affect cellular processes and the immune response. Cytosolic dsDNA is 
found to accumulate in response to DNA damage and this phenomenon is dependent 
on the ATM/ATR DDR pathway. However, the presence of cytosolic RNA:DNA 
hybrids appears to be independent of the DDR as treatment with the genotoxic agents 
did not increase the levels of cytosolic RNA:DNA hybrids, and blocking of ATM and 
ATR had no effect on the amounts of RNA:DNA hybrids in the cytosol. This 
prominent difference in the regulation of these nucleic acids suggests that derivation 
of nucleic acids may not be as closely associated, such that the sequences or genomic 
regions from which dsDNA is created are not similar to regions where RNA:DNA 
hybrids are derived. Cytosolic dsDNA accumulation is DNA damage-driven, 
suggesting a response mechanism that serves to repair the cell, and created dsDNA is 
due to severe lesion damage. In many of the cell lines and tumor tissues I studied, 
both dsDNA and RNA:DNA hybrids were constitutively present, suggesting that 
DDR activation was active in these cells. It would be interesting to test if primary 
cells have cytosolic RNA:DNA hybrids but absence of cytosolic dsDNA, and to 
determine the severity of DNA damage that would result in accumulation of dsDNA. 
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Conversely, if certain cells are abundant in either type of nucleic acid in the cytosol, 
the differences in cell damage state or gene expression might explain this discrepancy 
in accumulation. 
 One of the foremost possibilities for the source of cytosolic DNA is the 
release of mitochondrial DNA (mtDNA) into the cytosol after DNA damage. 
Oxidized mtDNA from the damaged mitochondria would activate the NLRP3 
inflammasome to trigger interferon and cytokine production (Shimada et al., 2012). 
However, we stained dsDNA with anti-8-oxo, a protein that targets the 8-oxo protein 
and ROS damaged DNA, and found no colocalization with dsDNA, suggesting that 
cytosolic dsDNA is not derived from damaged mitochondrial DNA. Further, 
Mitotracker stain did not co-stain with PicoGreen, nor did COX IV co-stain with 
either dsDNA or RNA:DNA hybrids, further corroborating the distinct character of 
these cytosolic nucleic acids as opposed to mitochondrial DNA.  
 Several lines of evidence point to these nucleic acids being derived from the 
nucleus. Sequencing of cytosolic DNA showed that many its sequences were derived 
from the genome, and no mitochondrial sequences were detected (Shen et al., 
manuscript submitted). Further, inhibition of RNA POL III prevented accumulation 
of cytosolic RNA:DNA hybrids while hybrids in the nucleus remained steady. Co-
stain of these nucleic acids also did not completely colocalize with Mitotracker or 
COX IV, eliminating the possibility of mitochondrial DNA. Further, treatment of 
Plasmocin and PenStrep ensured that infection was prevented as bacterial and viruses 
contribute to cytosolic DNA.  
Interestingly, we found that RNA POL III regulates RNA:DNA hybrid 
accumulation. RNA POL III functions as a transcription related enzyme, recruited as 
a cell undergoes replication, where it is required to supply tRNAs, along with 
transcription of ribosomal 5S rRNA and other non-coding RNAs (White, 2011). As 
RNA POL III binds basal transcription machinery within the nucleus, there is a 
possibility that hybrids are derived from transcription stalling of the transcription 
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complex. Recent studies hypothesize possible mechanisms for R-loop induced 
instability as a source of DSB (Hamperl and Cimprich, 2014). Thus it is possible that 
presence of RNA:DNA hybrids may precede accumulation of dsDNA that occurs 
with extensive DNA damage. It will be interesting to investigate the mechanisms by 
which these two types of nucleic acids could interplay with each other.  
Ara-C, the DNA damage agent that resulted in increased cytosolic dsDNA, is 
normally administered for chemotherapy, particularly in B cell lymphoma patients. It 
is metabolized into ara-CDP and ara-CTP, which act as alternative toxic nucleotides 
that are incorporated into the forming DNA from active transcription (Cros et al., 
2004). Ara-C disrupts cell replication by chain termination from the inability to bind 
further nucleotides for polymerase extension, along with DNA polymerase inhibition. 
Sustained replication stalling results in disintegration of the replication complex, and 
DNA repair mechanisms exist to ensure fidelity of the unwound DNA within the 
transcription bubble. During DSB repair, Rad50 and the MRN complex, which 
comprises of a protein trimer of MRE11-RAD50-NBS1, accumulate in response to 
DNA double-stranded breaks in the chromosome (Yuan and Chen, 2010). This 
complex is able to bind to damaged chromatin via the phosphorylation of MDC1 
(Spycher et al., 2008). Interestingly, Rad50 was identified as a potential dsDNA-
binding target in the mass spectrometry analysis of cytosolic lysate 
immunoprecipitation using dsDNA antibody. Rad50 activity is dependent on ATP 
(Kinoshita et al., 2009) and the MRN repair complex translocates to the cytoplasm 
following heat-shock and irradiation (Seno and Dynlacht, 2004). Thus cell stress 
induced by Ara-C along with dsDNA-bound proteins identified to be involved in 
early DSB repair suggest a role of early DNA repair in the accumulation of cytosolic 
dsDNA.  
Of note, Ara-C was dissolved in DMSO, which is known to affect cell 
membrane permeability (David, 1972; Shen et al., 2006). DMSO treatment was used 
as a negative control of Ara-C treatment, by adding the same volume of drug or 
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control. For example, 10uM (0.1% v/v.) of DMSO was added as control for Ara-C 
treatment. However, experiments with fixation of cells for cytosolic DNA, as well as 
for RNase H treatment on RNA:DNA hybrids, were performed in the absence of 
DMSO. These showed clear RNA:DNA hybrid staining, suggesting the reliability of 
the antibody stain. Further, comparison between Ara-C and DMSO treated cells 
clearly showed an increase in cytosolic staining, suggesting that Ara-C indeed 
resulted in increase of cytosolic DNA in cells after treatment, independent of any 
effect by DMSO. 
Another way by which cytosolic dsDNA could occur is with reverse 
transcription of transposons. LINE-1 retrotransposons were able to induce DSB in 
excess of LINE-1 insertions back into the genome (Gasior et al., 2006) in response to 
DNA damage, providing a route by which dsDNA and related nucleic acids could 
accumulate within the cell. As reverse transcription may occur independently of DNA 
damage, this may provide another explanation for the low levels of cytosolic dsDNA 
seen before addition of DNA damage agents.  
 
7.3 Detection of nucleic acids by staining 
To examine nucleic acid stains in the cells, a variety of nucleic acid stains 
was utilized. To distinguish between dsDNA and RNA:DNA hybrids, specific 
antibodies were primarily used. The PicoGreen dye used could have less distinction 
between the structure difference of dsDNA and RNA:DNA, which may affect the 
specificity of its intercalating nature.  
dsDNA antibodies were specific against cytosolic dsDNA, with either a weak 
or non-existent nuclear stain. We speculate that the cytosolic dsDNA that is 
recognized by the dsDNA antibody has been processed and is structurally or 
epigenetically different from the nuclear DNA from which it is derived. This would 
explain the weaker nuclear stain and distinct dsDNA cytosolic stain we see when 
using the dsDNA antibody for staining. dsDNA antibodies are essential in the 
 97 
diagnosis of certain autoimmune diseases, such as systemic lupus erythematosus 
syndrome. The dsDNA antibody clone, AE-2, was used to stain dsDNA of viral 
Porcine circovirus type 2 (PCV2) infecting lymph nodes and thymus of gnotobiotic 
piglets. In PCV-2 infected sections, cells in thymi were detected for cytoplasmic 
staining in addition to nuclei stain, and staining was specific to infected cells, 
indicating that the antibody might also have specificity for non-nuclear dsDNA 
(Hamberg et al., 2007). 
RNA:DNA hybrid antibodies (S9.6) have been widely used in publications in 
the detection of hybrid structures in the cell (Boguslawski et al., 1986; Hu et al., 
2006; Phillips et al., 2013). The kinetics and binding ability of the antibody has also 
been determined (Phillips et al., 2013), and it has been particularly useful in the area 
of detecting small RNA after probing on microarrays, down to 15 nucleotide length 
(Hu et al., 2006). This enables it to detect short strand RNA:DNA hybrids that might 
have escaped the detection by unspecific binding of dsDNA antibodies. This could 
also be one reason why the S9.6 cytosolic staining is more intense than dsDNA 
staining. Further, S9.6 antibody was also shown to have higher affinity for 
poly(I):poly(dC) hybrids as compared to poly(A):poly(dT) hybrids, suggesting that it 
might contain sequence specificity for its recognition criteria (Hu et al., 2006). While 
cytosolic RNA:DNA hybrids in human cells were described as viral or bacterial-
derived in previous published studies (Kailasan Vanaja et al., 2014; Rigby et al., 
2014), a study also suggested the presence of extranuclear RNA:DNA hybrids in 
yeast (Nakama et al., 2012). The authors speculated that the RNA:DNA hybrids are 
located in mitochondria as RNA:DNA hybrids were reported to form throughout the 
mitochondrial genome (Brown et al., 2008). However, staining of A549 cells for 
RNA:DNA hybrids and, mitochondrial markers showed that RNA:DNA hybrids are 
localized outside of mitochondria. RNA:DNA hybrids are also transiently formed 
during transcription and replication of genomic DNA (Kireeva et al., 2000; Aguilera 
and Garcia-Muse, 2012), however these are POL II-driven and located in the nucleus.  
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We also found that cytosolic RNA:DNA hybrids in tumor cells depend on 
transcription by POL III, while ssDNA and dsDNA are generated by DNA damage 
response-initiated events. However, it is conceivable that RNA:DNA hybrid 
contribute to the presence of ssDNA and dsDNA in tumor cells by stalling replication 
forks, which results in DNA damage and genomic instability (Hamperl and Cimprich, 
2014). Consistent with this conclusion, DNA damage response is activated in 
Rnaseh2-deficient cells (Hiller et al., 2012). Furthermore, overexpression of Rnaseh1, 
which degrades the RNA strand in RNA:DNA hybrids, decreased the levels of 
cytosolic ssDNA and dsDNA in tumor cells (Shen et al., manuscript submitted). 
PicoGreen has a chemical structure that is able to intercalate with dsDNA in 
sensitive amounts. PicoGreen fluorescence increases more than 1000-fold after 
binding to DNA; and PicoGreen dye exhibits high sensitivity, recognizing both 
polymeric DNA and short duplexes less than 20 base pairs. DNase I treatment 
decreased PicoGreen stain on nucleotides (Choi and Szoka, 2000). PicoGreen forms 
electrostatic contacts with DNA phosphate group, binding to the minor groove of 
DNA. PicoGreen spans four base pairs of the DNA structure, and its benzo-thiazol 
group has electrostatic interactions with DNA phosphate groups (Dragan et al., 2010). 
This suggests that PicoGreen binding recognition is based upon the DNA phosphate 
backbone, and has enriched binding to nucleotides. PicoGreen reagent also shows no 
bias towards either GC or AT rich regions, with both homopolymers having similar 
quantum yields of fluorescence efficiency when bound to PicoGreen (Singer et al., 
1997). However, experimental results of cells treated with RNase H showed a 
decrease in PicoGreen signal in the cytosol (Fig. 4.1), suggesting that PicoGreen 
might also recognize RNA:DNA hybrids, given the specificity of RNase H (Keller 
and Crouch, 1972). This is also supported by previous reports that showed PicoGreen 
also stains dsRNA at ten-times lower intensity than dsDNA (Singer et al., 1997), 
suggesting that RNA:DNA hybrids might also be recognized by the dye. Thus 
PicoGreen might not exclusively recognize dsDNA, and is able to stain for 
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RNA:DNA hybrids in cells. While strong nuclear signal of PicoGreen suggested that 
the large amounts of nuclear genomic dsDNA were stained, PicoGreen had high 
sensitivity that also allowed it to stain for less intense cytosolic signals in addition to 
the nuclear genome.  
In contrast, DAPI is an A-T sensitive dye that intercalates with the minor 
groove of DNA to form a fluorescent complex. Similarly, Hoechst dye 33258 
interacts preferentially with the minor groove of AT-rich sequences of a DNA duplex 
(Haq et al., 1997); showing more fluorescent yield as compared to DAPI. These two 
nuclear dyes are more commonly used for microscopy staining, however their 
sensitivity is less as compared to PicoGreen, partly due to their selective specificity.  
Furthermore, it is known that high nuclear staining of Hoechst can obscure 
mitochondria staining (Ligasova et al., 2013). Similarly, stains of cytosolic DNA 
would appear much weaker, and hence can be masked by strong Hoechst nuclear 
signal, a possible explanation for why DAPI and Hoechst could not stain for cytosolic 
DNA.    
 
7.4 Nature of dsDNA interactions with cytoplasmic proteins 
To examine the retention of DNA in the cytosol, a selection of DNA-binding 
proteins, DNA sensors, and compartmental proteins were co-stained with the DNA. 
However a representative colocalization of dsDNA antibody with another protein 
could not be identified. dsDNA is known to be stable in solution, and increases upon 
chaperoning with a binding protein (Williams et al., 2002). In addition, the presence 
of DNA in the cytosol seems contradictory to the body’s adverse reaction to aberrant 
endogenous DNA that is involved in inflammatory conditions.  
Different forms of DNase are found throughout the cell to ensure digestion of 
endogenous DNA (Hornung and Latz, 2010). DNase I is secreted into the 
extracellular space to prevent accumulation of DNA-containing immune complexes, 
and DNase II is found in acidic lysosomes that engulf apoptotic or necrotic cells. 
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DNase III (TREX1) is the only cytosolic DNase that is located on the endoplasmic 
reticulum. However, the presence of cytosolic DNA in cancer cell lines may suggest 
that DNA damage might cause a high turnover of DNA such that degradation is 
unable to keep up with its accumulation. In cells with particularly high rates of 
replication, fork stalling and translation may result in more DNA damage.  
Another possibility for cytosolic DNA accumulation in cancer cells lines, is 
the presence of defective TREX I that prevents DNA degradation. It is known the 
Trex1 knockout mice exhibit inflammation and have lower rates of survival (Morita 
et al., 2004), while TREX1 is associated in human autoimmune disease (Kavanagh et 
al., 2008). However, TREX1 is a 3’ to 5’ exonuclease that degrades ssDNA (Yang et 
al., 2007), although it is also said to act in concert with NM23-H1 endonuclease at 
nicked DNA regions (Chowdhury et al., 2006). The ssDNA is primarily produced 
through G1/S transition, as shown by the constitutive ATM-dependent checkpoint 
activation in deficient cells, and accumulates at the replication fork for TREX 1 to 
process. Hence if the cytosolic DNA is dsDNA, the TREX1 might not be able to 
recognize it as a suitable substrate for degradation, and its activity should not affect 
the stability of replication sites and DNA resection, which occurs during DSB repair.  
Another possibility is the presence of DNA-binding proteins that stabilize the 
cytosolic dsDNA and prevent its recognition by endonucleases. This is critical if the 
cytosolic DNA is functional in the cell. As DNA is able to encode information within 
a short sequence, it is perhaps a possibility that presence of DNA in damaged cells 
might serve a functional purpose.  
An immediate candidate for cytosolic DNA-binding proteins is the family of 
histones. Given that several lines of evidence show cytosolic DNA originating from 
the nucleus, it would be logical for histones to bind the DNA as it is chaperoned into 
the cytosol. In particular, citrullinated H3 was hypothesized to be a marker for 
cytosolic DNA as it was shown to be associated with transcription interference, and 
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thus sites of DNA damage. However, no colocalization was observed, even for H3 
citrullinated proteins.  
 
7.5 RNA POL III-dependent cytosolic RNA:DNA hybrids 
Each POL in the RNA POL family of proteins has defined transcriptional 
roles, where RNA POL I transcribes ribosomal RNA, RNA POL II transcribes 
protein-encoding mRNA, while RNA POL III transcribes 5S rRNA, tRNA, and 
certain retroelements (Weinmann and Roeder, 1974; Sentenac, 1985; Shilatifard, 
1998; Kuhn et al., 2007). Eukaryotic non-coding RNAs can be transcribed by all 
three polymerases (Goodrich and Kugel, 2006). Interestingly, inhibition of RNA POL 
III, abrogated the presence of cytosolic RNA:DNA hybrids suggesting that RNA POL 
III transcripts are required for the existence of such structures in the cytosol. In 
particular, nuclear RNA:DNA hybrids were not decreased after this treatment, 
consistent with previous reports that RNA:DNA hybrids in the nucleus are mainly 
from R-loops, a structure that is highly associated only with RNA POL II 
transcription machinery (Skourti-Stathaki et al., 2011). This raises the specificity of 
cytosolic RNA:DNA hybrids as RNA POL III-driven as opposed to nuclear 
RNA:DNA hybrids being mainly RNA POL II-driven.  
RNA POL III is shown to increase SINE transcription upon heat shock, a 
form of cell stress, and these transcripts can repress mRNA transcription (Ponicsan et 
al., 2010). This presents a form of gene regulation via POL III; in particular 
RNA:DNA hybrids are most likely formed through reverse-transcription of 
retrotransposons  Recently, endogenous siRNAs (endo-siRNA) were shown to be 
present in cells, and these endo-siRNAs were decreased in human breast cancer cells 
as compared to normal breast cells (Chen et al., 2012), along with expression of 
endo-siRNAs being able to silence LINE-1 retrotransposons through increased DNA 
methylation. RNA polymerase III transcribes non-coding RNAs that may be 
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processed into endo-siRNAs. In this way, RNA:DNA hybrids that bind to AGO2 may 
be a product of this inhibition, as endo-siRNAs are derived from mobile elements in 
the genome. However, previous research within the lab performed overexpression of 
open reading frame (ORF) 1 and ORF2 proteins in cells, where these proteins are 
encoded by LINE-1 and function to help retrotransposition (Feng et al., 1996; Moran 
et al., 1996). These cells showed no change in cytosolic DNA levels, suggesting that 
reverse transcription of retroelements did not play a role in the accumulation of these 
cytosolic nucleic acids. 
Although MRC-5 cells were shown to have cytosolic DNA, they were 
invariant to RNA POL III expression. BRCA1 has been shown to inhibit RNA POL 
III transcription in a cell specific manner (also in Hela) (Veras et al., 2009), hence 
RNA POL III-driving of RNA:DNA hybrids might be cell type specific. We have 
shown that endogenous RNA:DNA hybrids are present in human lymphoma tissues. 
Presence of EBV infection in the patient could be a possible explanation for high 
amounts of RNA:DNA hybrids, however the datasheet of the tissues that showed the 
exact stage and type of lymphoma, did not state that the tissues were EBV infected. 
Further, we have also stained other tissue samples and found that pancreatic cancer 
tissues exhibit similar specificity of RNA:DNA hybrid accumulation. Nevertheless, 
the role of RNA POL III in transcription and overexpression leads to high 
proliferation and tumorigenesis, relating its relevance to tumorigenesis. 
 
7.6 Role of DDX17 in DNA damage and miRNA biogenesis 
DDX17 has been shown to be involved in transcriptional regulation in 
addition to its role in miRNA processing. DDX17 along with its related DDX5 
protein have been associated with cancer, as they modulate p53, and Drosha, to 
regulate processing of oncomirs (Bates et al., 2005; Dardenne et al., 2014). DDX17 
has also previously been implicated in cell proliferation towards tumorigenesis 
(Dardenne et al., 2012). In addition, DDX5 also activates p53 tumor suppressor in 
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response to DNA damage, but is tissue and context-dependent for the induction of 
apoptosis (Nicol et al., 2012).  I detected the presence of peptides from putative 
DDX5/DDX17 in both dsDNA and RNA:DNA hybrid immunoprecipitated cytosolic 
lysates, in mass spectrometry. Further, DDX17 knockdown increased cytosolic 
dsDNA stains in cells, and it was shown via immunoblot that DDX17 protein bound 
to RNA:DNA hybrids. Off-target effects might have been an explanation for increase 
of cytosolic DNA after siRNA. However, we used NCBI BLAST 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) to analyse the siDDX17 #3 sequence, which 
showed 100% sequence coverage towards DDX17, with the next sequence-
compatible protein (KRAB-A domain containing 2, KRBA2) matching only 66% 
query coverage. On the other hand, siDDX17 #1 sequence had the next sequence-
compatible protein (heterochromatin protein 1, binding protein 3, HP1BP3) matching 
71% query coverage. This suggested that siDDX17 #3 had less off-target effects 
based on its sequence specificity. Interestingly, previous studies showed that DDX17 
knockout mouse embryo fibroblasts also had reduced ribosomal RNA (rRNA) 
expression (Fukuda et al., 2007), similar to the disappearance of cytosolic dsDNA in 
response to DDX17 knockdown in A549 cells. One possible explanation could be the 
accumulation of dsDNA and RNA:DNA hybrids is dependent on DDX17 expression.  
 Recently, DDX17 has been shown to be a multi-tasking regulator (Fuller-
Pace, 2013), and DDX5/DDX17 helicase activity was hypothesized to favor binding 
to G-quadruplexes (Dardenne et al., 2014). Nevertheless, although DDX17 is a 
putative RNA helicase, it is not known if this function extends for DNA. Further, 
DDX17 also regulates gene expression by regulating alternative splicing of DNA-
binding factors such as macroH2A1 (Dardenne et al., 2012), suggesting another role 
of DDX17 that might contribute to the release of cytosolic nucleic acids.  We showed 
that DNA damage associated with upregulation of cytosolic DNA and DDX17, yet 
DDX17 knockdown resulted in increased cytosolic dsDNA. This conundrum has yet 
to be fully addressed; however we suggest an explanation as follows. DDX17 is a 
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RNA helicase, and it is also known to play a variety of roles in relation to 
tumorigenesis, as reviewed by Fuller-Pace and Moore (Fuller-Pace and Moore, 
2011). It could be possible that the function of DDX17 may differ according to the 
location in which it is found. DDX17 is a RNA helicase that is able to separate 
dsRNA to single strands (Lin et al., 2005), and it may also help to unwind dsDNA in 
the cytosol, thus degrading cytosolic dsDNA. However in the presence of Ara-C 
damage, DDX17 may be unable to cope with the increase of cytosolic dsDNA due to 
widespread nuclear DNA damage. Further experiments such as inhibition of nuclear 
export in the presence of DNA damage would address such questions. 
Moreover, as dsDNA and RNA:DNA hybrids were shown to be dependent 
on different mechanisms (DDR-dependent vs. non-DDR-dependent), one might 
postulate that DDX17 might affect the accumulation of these two species of nucleic 
acids in different mechanisms. This might be possible due to the multi-functional 
roles of DDX17.  
 
7.7 MiRNA expression and RNA:DNA hybrids 
MiRNAs require export from the nucleus to the cytoplasm as part of their 
biogenesis. DNA damage induces an ATM-dependent miRNA expression profile that 
is regulated by transport through the exportin-5 (XPO-5) bound nuclear pore complex 
(Wan et al., 2013). While DNA damage increased dsDNA cytosolic accumulation, 
RNA:DNA hybrids were not found to be highly accumulated in the cytosol in 
response. This suggested separate pathways of regulation for these two types of 
nucleic acids in response to DNA damage.  
 RNA POL III was previously found to affect miRNA accumulation. Here, we 
show that inhibition of RNA POL III activity affected miRNA expression, with 
affected gene targets regulated in pathways in RNA transport and RNA surveillance. 
Analysis of the miRNA expression profile showed that RNA POL III modulates the 
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expression of a small number of miRNAs, most of which were upregulated upon 
RNA POL III inhibition, suggesting a complex regulation of these miRNAs by RNA 
POL III in A549 cells. Surprisingly, RNA POL III inhibition reduced the expression 
of only four miRNAs. Three out of the four miRNAs were also downregulated by 
Ara-C, which does not modulate the levels of cytosolic RNA:DNA hybrids. Hence, 
our data would suggest that cytosolic RNA:DNA hybrids consist of very limited 
number of POL III-transcribed miRNAs, possibly only miR-4499.  
Alternatively, it is conceivable that POL III-modulated miRNAs target 
transcripts of genes, which regulate the presence of cytosolic RNA:DNA hybrids. 
Consistent with this possibility, many POL III modulated miRNAs potentially target 
RNA transport and mRNA stability pathways. Cytosolic RNA:DNA hybrids may 
also be generated by the transcription of cytosolic DNA by POL III, which was 
reported to detect cytosolic DNA and induce type I interferons through the RIG-I 
pathway (Schwartz et al., 1974; Jaehning and Roeder, 1977; Chiu et al., 2009). 
However, POL III did not co-localize with cytosolic DNA or cytosolic RNA:DNA 
hybrids.  
MiRNA has been associated with tumorigenesis and cancer. Further, 
dysregulated RNA POL III correlates with tumor progression, and RNA POL III 
transcribed open reading frames occur with cancerous cell lines, suggesting an 
increase in transcription of genes in response to RNA POL III, thus providing a 
mechanism to increase generation of RNA:DNA hybrids. 
A pathway analysis of potential target genes from the identified miRNAs 
showed that RNA transport and mRNA surveillance pathways were affected. This is 
consistent with the possibility that regulation of miRNAs and RNA:DNA hybrids via 
RNA POL III affects cancer progression. Some genes of these pathways were further 
quantified to respond to RNA POL III treatment in accordance with the miRNA 
microarray analysis. 
 106 
Finally, it is conceivable that reverse transcription of RNA POL III-
transcribed retroelements produces RNA:DNA intermediates in the cytosol similar to 
replicating RNA viruses. It would be interesting to investigate mir-4499 transcription 
or expression, which is more specific to RNA POL III regulation. A functional 
knockdown of the mir-4499 to determine its effect on cytosolic RNA:DNA hybrids 
might help to uncover its role in response to RNA POL III inhibition.  
 
7.8 Innate immune signaling of nucleic acids 
Nucleic acids are key activators of the innate immune system, with 
intracellular DNA and RNA acting as PAMPs during infection, and DAMPs after 
DNA damage. Here, we found the presence of dsDNA and RNA:DNA hybrids in 
tumorigenic cell lines. The significance of these cytosolic nucleic acids has yet to hint 
at a role for innate signaling. Although interferon levels were not significantly 
affected after treatment of RNA POL III that inhibits RNA:DNA hybrid 
accumulation, little is known if differential accumulation of RNA:DNA hybrids may 
affect tumor recognition in vivo. Alternatively, other pathways of immune signaling 
may also play a role in RNA:DNA hybrid sensing; the NLRP3 inflammasome 
pathway was shown to be activated by bacterial RNA:DNA hybrids inducing IL-1β 
production (Kailasan Vanaja et al., 2014). Intriguingly, we also observed a distinct 
detection of RNA:DNA hybrids in cancer tissues as compared to normal tissues, 
suggesting that RNA:DNA hybrids were selectively present in a cancer 
microenvironment. Further, as RNA:DNA hybrids were shown to activate the 
pathways involved in immune sensing (Kailasan Vanaja et al., 2014; Rigby et al., 
2014), it is postulated that the presence of RNA:DNA hybrids in cancer tissues might 
activate a similar immune response. Given the correlation of the immune system with 
cancer, as reviewed by Schulz (Schulz, 2009), it would be interesting to examine the 
recruitment of immune cells in response to the presence of RNA:DNA hybrids at 
cancer sites or sites of DNA damage in vivo. 
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 In addition to intracellular DNA, release of DNA from dying cells via 
necrosis is also recognized as a ‘danger’ signal in response to treatment of alum as a 
vaccine adjuvant (Marichal et al., 2011). In autoimmune diseases such as SLE, 
dysregulation of DNases play a major role in disease progression. While we tried to 
express DNase I in the cytosol by tagging the protein to the cell membrane, cells 
expressing DNase I exhibited high levels of cell death, possibly due to degradation of 
the genome during replication, where the nuclear envelope disintegrates and the 
genomic DNA is exposed to highly expressed cytosolic DNase I. This suggests that 
mechanism of cytosolic DNA production proceeds at a rapid rate as compared to 
degradation by DNase I. Another possibility is the presence of cytosolic DNA that is 
stably expressed with modifications that prevent it from being degraded by DNase I.  
 DNase II is predominantly expressed in lysosomes and exhibits high kinetics 
at low pH (Liu et al., 2008). It functions to degrade apoptotic DNA engulfed from 
nearby ‘dying’ cells, and its importance is underscored by the fact that DNase II-
deficient mice are embryonically lethal, with undigested DNA accumulated in 
macrophages along with high levels of interferon-beta (Okabe et al., 2005; Yoshida et 
al., 2005). However staining for lysosomes and other compartment markers along 
with dsDNA found no distinct correlation between the two stains, suggesting that 
dsDNA did not accumulate in these compartments, thus DNase II might not have a 
regulatory role in the production of dsDNA or these cytosolic nucleic acids.  
Previous studies have shown the presence of DNA damage along with 
cytosolic DNA in murine tumor cells, suggesting that cytosolic DNA functions as an 
endogenous DAMP trigger for the immune response to affect tumor progression 
(Lam et al., 2014a). In my study, I focused on the presence of cytosolic nucleic acids 
in human cancer cell lines. Interestingly, the THP-1 human monocytic cell line 
derived from acute monocytic leukemia also stained positive for RNA:DNA hybrids. 
As such, tracking of tumor progression in the B-cell lymphoma mouse model, Eµ-
Myc mice, with the presence of RNA POL III and its effect on cytosolic RNA:DNA 
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accumulation might provide insight into how levels of RNA:DNA associate with the 
initial regression of Eµ-Myc B cell tumors and eventual reemergence of the leukemia. 
In addition, while RNA:DNA has been shown to be immunologically active in DCs 
(Rigby et al., 2014), its role in fibroblasts and other immune cells have yet to be 
analyzed. An understanding of the effect of RNA:DNA hybrid accumulation in 
modulating immune response would open up an alternative substrate to DNA sensors 
in the detection of DAMPs in tumorigenic cells.  
  
7.9 Tumor progression in Eµ-Myc mice 
Translational suppression occurs with integrated stress upon cells and the 
formation of stress granules in the cytoplasm that contain high amounts of RNA from 
stalled ribosomes (Buchan and Parker, 2009). ZBP1 was found to colocalize with 
stress granules in response to oxidative stress, and although it was not required for 
stress granule assembly (Stohr et al., 2006). It was found to associate and stabilize 
mRNA transcripts in stress granules. ZBP1 intracellular localization was dependent 
on its Z-DNA binding domain, where mutation of that domain resulted in a different 
cytosolic distribution of ZBP1 in cells, in response to stress (Deigendesch et al., 
2006). ZBP1 was also found to be a cytosolic DNA sensor signaling through the 
TBK1/IRF3 pathway to activate IFN (Takaoka et al., 2007). Interestingly, data from 
our lab showed that Zbp1-/-Eµ-Myc mice displayed lower amounts of cytosolic 
dsDNA in tumor cells, in contrast to Eµ-Myc mice (Lam et al., manuscript 
submitted). Thus, in order to investigate if the phenotype of B cell lymphoma in Eµ-
Myc mice is due to the ZBP1 signaling pathway through TBK1 with IRF3, I crossed 
Tnfa/Tbk1, and Tnfa-deficient mice, with Eµ-Myc mice. In addition to ZBP1, 
TBK1 is also a mediator of other DNA sensing pathways, as it was able to mount an 
interferon response to DNA in the absence of ZBP1 (Takaoka et al., 2007; Ishii et al., 
2008) TBK1 was activated in response to DNA damage, and this process was 
dependent on the DDR (Lam et al., 2014a). TNF is a proinflammatory cytokine that 
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is activated in response to DNA sensing (Ivanov et al., 2007), and stimulate immune 
cells such as neutrophils and macrophages (Peterson et al., 2006). Hence, we also 
determined if Tnfa deficiency could affect tumor progression Eµ-Myc mice. 
 
Results showed that Tnfa/Tbk1 and Tnfa-deficient Eµ-Myc mice exhibited 
higher and rapid mortality rates with a high tumor load even during regression phase 
from day 40-60. TNF itself is able to activate pathways leading to induction of 
proinflammatory cytokines or genes involved with survival (Balkwill, 2009). 
Recombinant TNF is able to cause necrosis of tumors, along with the activation of 
cell killing via CD8+ T cell and NK cells (Kashii et al., 1999; Prevost-Blondel et al., 
2000). Given that Eµ-Myc mice are dependent upon NK and T cells for tumor cell 
killing (Croxford et al., 2013), decreased Tnfa expression affected tumor load in Eµ-
Myc mice, consistent with observations. The effect of TNF may mask the 
contribution of TBK1 towards progression of B cell tumors in mice, however the 
surprisingly low tumor load of Tnfa-/-Tbk1-/-Eµ-Myc mice suggests other regulatory 
mechanisms that replace this pathway in the absence of both TNF and TBK1.   
In this thesis, we showed that siRNA of RNA Pol III, and Pol III inhibitor 
treatment did not reduce interferon mRNA expression, suggesting that the interferon 
pathway was not activated via cytosolic RNA:DNA hybrids. TNF and interferon 
levels triggered by poly (dA:dT) were previously found to be dependent on RIG-I and 
RNA polymerase III, a purported DNA sensor (Ablasser et al., 2009). However, 
IFNα release in infected plasmacytoid DCs (pDCs) was also found to be suppressed 
by TNF (Palucka et al., 2005). A possilibity for our lack of interferon detection could 
be due to RNA:DNA hybrids activating TNF secretion instead of IFNα in cancer 
cells. This would suggest that TNF might act as another arm of immunosurveillance 
in Eµ-Myc mouse tumors. 
Recently, cGAS was identified to be the second messenger that transduces 
the sensing cytosolic DNA into interferon expression for host immune response (Gao 
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et al., 2013; Li et al., 2013; Sun et al., 2013). Further, STING as an adaptor protein in 
phosphorylation of IRF3 was confirmed to act downstream of cGAS activation, 
providing a new perspective of DNA sensing (Wu et al., 2013). The existence of this 
pathway elevates the importance of STING as a linchpin protein in the activation of 
the interferon response. Thus it would be interesting to cross Eµ-Myc mice with 
Sting-deficient mice and observe tumor regression phase. Although we did not 
observe strong colocalization of STING and cytosolic dsDNA, STING might act 
downstream of a DNA sensor of dsDNA to trigger an immune response. Thus, one 
might expect that loss of STING leads to higher accumulation of cytosolic DNA 
without activation of the host immune system, allowing for rapid proliferation of B 
cell tumors without any regression phase as NK and T cells are unable to recognize 
signals for tumor-cell mediating killing. Given that the Tnfa-deficient Eµ-Myc mice 
died earlier, the activation of the immune response serves as an important player in 
the mortality of B cell tumors, and STING might represent a possible key player in 
tumorigenesis. Tumor progression of Sting-deficient Eµ-Myc would therefore present 




In summary, our results demonstrate the presence of cytosolic dsDNA and 
the first instance of RNA:DNA hybrids in a variety non-infected human cells, and in 
human lymphoma tissues for RNA:DNA hybrids. While cytosolic dsDNA is 
dependent upon DDR, RNA:DNA hybrids are independent of DDR, but are instead 
regulated by RNA POL III.  Further, RNA:DNA hybrids bind to proteins of the 
miRNA machinery, DDX17 and AGO2. POL III inhibition also targets miRNAs 
involved in RNA transport and surveillance. Investigation of Eµ-Myc mice 
tumorigenesis revealed the importance of TNF-α in tumor cell killing, while the 
function of TBK1 remains to be revealed. These findings extend the knowledge in the 
field of nucleic acids in cells for DNA-sensing, and enhance the characterization of 
molecules that can be targeted for cancer immunotherapy.   
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Appendix A. Extract of Mass Spectrometry Mascot Search Results 
 
 
Mascot Search Engine was used to analyze peptides detected from cutout gel regions 
of interest after A549 cytosolic lysate immunoprecipitation with either RNA:DNA 
hybrid antibodies or dsDNA antibodies. (a, b) Mass spectrometry analysis from Fig. 
4.9 showing DDX17 and AGO2 as interacting proteins of RNA:DNA hybrids. (c) 
Mass spectrometry analysis from Fig. 3.10 identifies DDX17 as an interacting protein 
of dsDNA. 
